2013 R
EPORT
Neurological disorders—such as epi-lepsy, multiple sclerosis and Parkinson’s disease—inflict great pain and suffering on patients and their families, and every year costs the U.S. economy billions of dollars. Biopharmaceutical research companies are developing 444 new medicines to prevent and treat neu-rological disorders. The medicines in development are either in human clinical trials or under review at the Food and Drug Administration. They include:
• 82 medicines for Alzheimer’s disease, which afflicts more than 5 million Americans.
• 82 medicines for pain—100 million U.S. adults experience chronic pain.
• 62 medicines for brain tumors—nearly 70,000 Americans are diagnosed each year with a primary brain tumor.
• 38 medicines for multiple sclerosis, which afflicts an estimated 500,000 Americans.
• 28 medicines for epilepsy and sei-zures, which impact more than 3 million Americans.
• 27 medicines for Parkinson’s disease, which affects as many as 1 million Americans.
• 25 medicines for headache, includ-ing migraine, a condition that affects more than 37 million people.
Other medicines in development target amyotrophic lateral sclerosis (ALS), brain injuries, Huntington’s disease, spinal cord injury, cerebral palsy, and stroke. Among the many promising new medicines in development are:
• A medicine that prompts the immune system to protect neurons affected by ALS.
• Gene therapy for the treatment of Alzheimer’s disease.
• Gene therapy to reverse the effects of Parkinson’s disease.
The new medicines being developed by biopharmaceutical research companies reflect a growing understanding of the underlying mechanisms of neurological disorders, which fuels scientific progress and pharmaceutical research. These medi-cines offer patients hope that more effec-tive treatments may soon be available.
Biopharmaceutical Companies Researching and Developing Nearly 450 Medicines for Neurological Disorders
MeDiCiNes iN DevelopMeNt
Neurological DisordersA Report on Disorders of the Brain, spinal Cord and Nerves
presented by america’s biopharmaceutical research companies
Mul
tiple
Scler
osis
Pain
Park
inso
n’s
Brain
Tum
ors
Alzh
eimer
’s
82 82
62
28 27
Epile
psy
38
Application Submitted
Phase III
Phase II
Phase I
Medicines in Development For Neurological Disorders
Contents Key Issues ......................................2Disease Facts ..................................7Medicines in Development ...............11Glossary ...................................... 49Drug Development/ Approval Process ....................... 51
Medicines in Development neurological disorders 20132
innovative Medicines in the PipelineOf the 444 medicines in development in the United States listed in this report (see page 11), many present innovative new ways to target diseases. Some of them include:
• Gene Therapy to Restore Neuronal Function in Alzheimer’s—A gene therapy for the treatment of Alzheimer’s disease in clinical trials is designed to deliver nerve growth factor (NGF) to the brain. NGF is a naturally occurring protein important for neuron survival. The gene treatment is injected into the brain region where neuron degeneration occurs in Alzheimer’s disease. It is thought that the result-ing sustained expression of NGF in the neurons can restore their lost function, leading to memory and cognition improvement.
• Targeted RNAi Therapy Approach for Duchenne Muscular Dystrophy—In clinical trials, RNAi therapies have shown potential in treating neuromuscular dis-
orders such as Duchenne muscular dystrophy (DMD). In DMD, DNA deletions cause mutations in important genes that encode for dystrophin, a structural pro-tein found in normal muscle. The loss of this protein causes muscle fibers to disintegrate faster than they can be regenerated. One medicine in development targets restoration of dystrophin function and, as dys-trophin expression increases, there have been demon-strated improvements in patients’ ability to walk.
• Gene Therapy as a Possible Approach for Parkinson’s Disease—Inserting genes into cells can alter the im-pact the genes have on the proteins that are involved in a particular disease. These genes might alter or replace a mutated gene or produce a new thera-peutic protein entirely. In Parkinson’s disease, there are a number of treatments addressing the disease’s symptoms, but none that replace the lost nerve cells resulting from Parkinson’s or that would stop disease progression. More than one gene therapy in clinical trials uses an adeno-associated virus (AAV) as a vector
82
28
8
19
8
62
14
82
25
7
7
38
27
6
9
19
Epilepsy
Genetic Disorders
Brain Tumors
Amyotrophic Lateral Sclerosis (ALS)
Brain Injury
Attention-Deficit/Hyperactivity Disorder
Alzheimer’s Disease
Parkinson’s Disease
Spasticity
Spinal Cord Injury
Stroke
33Other
Pain
Huntington’s Disease
Muscular Dystrophy
Multiple Sclerosis
Headache
Application Submitted
Phase III
Phase II
Phase I
Medicines in Development for Neurological Disorders By Disease and Phase
Some medicines are listed in more than one category
Medicines in Development neurological disorders 2013 3
to deliver neurturin to restore cells damaged in Parkinson’s patients and to protect them from fur-ther degeneration; these inactivated viruses pres-ent a safe way to get these important therapeutic options to patients.
• Als: Fighting a Devastating Disease—ALS, or Lou Gehrig’s disease, is a progressive neurode-generative disease that causes the brain to lose control over body movement, ultimately resulting in paralysis and death. The one drug approved to treat ALS can modestly slow progression of the disease, but new treatments are needed. As our scientific understanding of the disease has grown, researchers are pursuing many new approaches to halt or slow disease, including the use of the patient’s own bone marrow stem-cells to cre-ate healthy neuron-like cells to replace diseased neurons. Other trials are studying ways to prompt the immune system to protect neurons affected by ALS.
alzheimer’s: effective treatment is needed
Alzheimer’s is the 6th leading cause of death in the United States, and its impact on patients and the health care system is growing. Existing medicines are able to treat the symptoms of the disease but cannot slow, prevent, or reverse the progressive dementia. Disease-modifying treatments that could delay the onset of the disease could reduce the cost of care of Alzheimer’s patients in 2050 by $447 billion. Researchers continue to unravel the mysteries of the disease and are studying many new treatments in this area. Recent research has focused on the plaques and tangles which form in the brains of Alzheimer’s patients and are thought to contribute to the death of nerve cells. One medicine in development has shown promise in reducing both brain plaques and tangles. A gene therapy also in clinical trials is being explored to restore lost neuron function.
ALZHEIMER’S COSTS SOCIETY $203 BILLION AND COULD INCREASE TO $1.2 TRILLION BY 2050
ALZHEIMER’S COSTS SOCIETY $203 BILLION AND COULD INCREASE TO $1.2 TRILLION BY 2050
DELAYING DISEASE ONSET BY 5 YEARS COULD RESULT IN50% FEWER PATIENTS/SAVE $447 BILLION BY 2050DELAYING DISEASE ONSET BY 5 YEARS COULD RESULT IN50% FEWER PATIENTS/SAVE $447 BILLION BY 2050
ARE LIVING WITH ALZHEIMER’S DISEASEARE LIVING WITH ALZHEIMER’S DISEASE
BY 2050, THE NUMBER OF PATIENTS COULD TRIPLE WITHOUT EFFECTIVE TREATMENT
BY 2050, THE NUMBER OF PATIENTS COULD TRIPLE WITHOUT EFFECTIVE TREATMENT
5
5
$203
FEWERVICTIMS
YEARSDELAYEDONSET
AMERICANS
2013
SAVED
BILLION
$447 50%BILLION
$1.22050
TRILLION
+=
MILLION
AMERICANSMILLION15
IMPORTANCE TREATMENTALZHEIMER’SOF
Medicines in Development neurological disorders 20134
Advancing Biomedical science Over the past decade, scientific advances and new technolo-gies have dramatically changed how medicines are discov-ered. This new information is critical to the development of new treatments for neurological disorders. Greater knowl-edge of how diseases work at the genetic and molecular level has allowed researchers to pursue new targets for therapy and better predict how certain biopharmaceuticals will affect specific subpopulations of patients.
• Bioinformatics—Bioinformatics use systems and mathematical models to advance the scientific un-derstanding of living systems. At its simplest level, bioinformatics involves the creation and maintenance of biological databases, including DNA sequences.
• Biomarkers—Every disease leaves a signature of molecular “biomarkers” in our body—genes that turn on and off or proteins released into the bloodstream. Biomarkers measured in blood and other samples can tell us the state of our health and how we might respond to treatment.
• Molecular Targeting—The idea behind molecular targeting is to design drugs that specifically attack the molecular pathways that cause disease without dis-rupting the normal functions in our cells and tissues.
• Nanotechnology—You can’t see it, but soon it will be everywhere. Nanotechnology is the science of build-ing microscopic devices at the molecular and atomic levels. In medicine, nanotechnology may also be used to help diagnose and treat diseases.
• Personalized Medicine—The sequencing of the human genome produced a “map” of the human genes in DNA. This new genetic knowledge opens up the possibility of developing “targeted” therapies for people with specific gene sequences, and it can help physicians choose the best treatments based on individual genetic, lifestyle, and environmental factors.
Breakthrough Research in Neurological DisordersEarly research discoveries often fuel the drug development pathways that biopharmaceutical company researchers un-dertake. These discoveries help researchers target a specific disease through certain mechanisms that may have been unknown before. Some noteworthy recent scientific discover-ies in the field of neurology include:
• Researchers at Mount Sinai Medical Center found 10 genes that account for half of the genetic risk for Alzheimer’s.
• Research at the National Institutes of Health found that a protein linked with some early-onset Parkin-son’s disease cases regulates how the body processes dietary fats. The study suggests there could be a link between the defective protein and early-onset Parkin-son’s disease.
• Scientists at the University of Chicago have uncovered a previously unknown process of protein production where a single gene can create two separate proteins from the same messenger RNA simultaneously. They believe this discovery will open the door for new research into therapies for neurological disorders.
• Research at the University of Missouri suggests that two identical neurons can reach the same electrical activity in different ways and could help doctors in treating patients with epilepsy.
• Two separate research groups have identified a muta-tion on the TREM2 gene that may increase a person’s chance of developing late-stage Alzheimer’s disease by three to five times.
• While studying at PennVet, a researcher discovered the gene responsible for Alexander disease, a rare, genetic neurological disorder where the white matter in the brain is destroyed and Rosenthal fibers form causing both mental and physical declines.
Medicines in Development neurological disorders 2013 5
• At the University of Notre Dame, researchers have created a prodrug (an inactive drug that is converted into its active form once it’s in the body) of an inhibi-tor of the gelatinase enzyme. Gelatinase is associated with certain neurological disorders, such as strokes, aneurysms and traumatic brain injury.
• Researchers at the Manchester Institute of Biotech-nology in the United Kingdom have identified an enzyme in the brain that interacts with a compound for Huntington’s disease to inhibit its activity. Animal studies have shown that by switching off the enzyme’s activity through drug-binding, the enzyme is effec-tive in treating brain disorders such as Huntington’s, Alzheimer’s, and Parkinson’s.
the brain initiative
Brain Research through Advancing Innovative Neurotechnologies is a research effort launched by the Obama Administration to map the human brain and increase our understanding of how the human mind works. Approximately $100 million will be directed to government agencies, such as the National Institutes of Health, beginning in FY 2014. The BRAIN Initiative aims to accelerate the development and application of new technologies to help researchers understand the interworking’s of the brain, leading to new ways to treat and maybe one day prevent or cure diseases, such as Alzheimer’s, epilepsy and traumatic brain injury.
Public/Private Partnerships Critical to Advancing scienceCollaboration among partners in the entire medical innovation ecosystem is critical to help advance scientific understanding of some of the most complex diseases facing patients. Federal research institutions, academia, biopharmaceutical research companies and patient communities all play an important role in furthering research in the neurological field.
These evolving partnerships take many forms, for example:
• One biopharmaceutical company recently formed a research consortium to bring together several lead-ing academic research centers to coordinate their research and share results. Through this collaboration, researchers hope to accelerate their understanding of the disease and identify new approaches for targeting and treating amyotrophic lateral sclerosis (ALS).
• The Alzheimer’s Disease Neuroimaging Initiative is a collaborative effort between several federal agen-cies, non-profit organizations, and biopharmaceutical industry members. The goal of the Initiative is to track Alzheimer’s disease progression, establish quality stan-dards, and validate biomarkers to be used in clinical
trials. Data collected are made available at no cost to researchers when designing clinical trials and research projects.
• Another biopharmaceutical company is collaborating with a medical school’s neurodegenerative disease research center to screen for Alzheimer’s drug can-didates. The company is sharing their basic research with the research center’s screening assays and knowledge of the biology of the tau protein, which is thought to play a significant role in Alzheimer’s disease.
• The Coalition Against Major Diseases, a program of the Critical Path Institute, is a consortium of biophar-maceutical research companies, academic institu-tions, regulatory agencies, patient advocacy groups, research foundations, scientific associations and consultants that work collaboratively through a pre-competitive partnership to accelerate development of therapeutics for neurodegenerative diseases.
Medicines in Development neurological disorders 20136
New Neurological Medicines Approved for PatientsThe new medicines being developed today build on the medical progress seen over the last decade or so. Below are exam-ples of innovative medicines approved recently to treat some neurological conditions.
Attention-Deficit/Hyperactivity Disorder (ADHD)
• vyvanse® (lisdexamphetamine dimesylate) is the first stimulant prodrug approved for the treatment of ADHD. It is an oral biologic medicine that is thera-peutically inactive until metabolized in the body. It is intended to provide a safer, abuse-resistant and effec-tive alternative to amphetamine-based therapies for ADHD.
Alzheimer’s Disease
• Namenda® (memantine) is the first treatment ap-proved for moderate to severe Alzheimer’s disease. It was also the first in a new class of medicines called NMDA receptor antagonists to be approved for the disease. Namenda interferes with the effects of excess glutamate release—glutamate plays a key role in the neural pathways associated with learning and memory.
Multiple Sclerosis (MS)
• Tecfidera™ (dimethyl fumarate; BG-12) is a first-line oral treatment for relapsing forms of MS. It is be-lieved to treat the disease in a new way by stimulating the Nrf2 transcriptional pathway that provides a way for cells in the body to defend against inflamma-tion and neuronal death that is induced by oxidative stress. In clinical trials it was shown to reduce relapses and the development of brain lesions, as well as slow disability progression.
• Gilenya® (fingolimod) is a first-in-class oral medicine also approved to treat relapsing forms of MS. With a different mechanism of action, it binds to the S1PR lipid and traps certain white blood cells in the lymph nodes, thereby reducing the immune system’s attack on the central nervous system (CNS). By preventing the blood cells from reaching the CNS where they can damage the covering around the nerve fibers, this medicine can reduce damage to the nerve cells.
Seizures
• Potiga® (ezogabine) is a first-in-class potassium chan-nel blocker approved for the adjunctive treatment of partial-onset seizures in adults. While the exact mech-anism of action is unknown, it is believed to work by opening the potassium channels, which are thought to stabilize the neurons and reduce brain excitability.
Medicines in Development neurological disorders 2013 7
Brain Tumors4
Amyotrophic Lateral Sclerosis2
Brain Injury3
Alzheimer’s Disease and Other Dementias1
• An estimated 69,720 new cases of primary brain tumors (those that begin and tend to stay in the brain) are expected to be diagnosed in 2013, including both malignant (24,620) and non-malignant (45,100) brain tumors.
• In 2010, more than 688,096 people in the United States were living with the diagnosis of a primary brain or central ner-vous system tumor—more than 138,054 were malignant tumors and more than 550,042 were non-malignant.
• Gliomas, a broad term which includes all tumors arising from the gluey or supportive tissue of the brain, represent 30 percent of all brain tumors and 80 percent of all malignant tumors. Glioblastomas represent 17 percent of all primary brain tumors and 54 percent of all gliomas.
• An estimated 30,000 Americans may have amyotrophic lateral sclerosis (Als) at any given time, and some 5,600 people in the United States are diagnosed with ALS each year. It is estimated that ALS is responsible for nearly 2 deaths per 100,000 population annually.
• According to the U.S. Centers for Disease Control (CDC) Injury Prevention Center, the leading causes of traumatic brain in-jury (TBi) are: falls, 35.2 percent; unknown/other, 21 percent; motor vehicle, 17.3 percent; head strikes, 16.5 percent; assault, 10 percent.
• Traumatic brain injury is the leading cause of disability and death in children and adolescents in the United States. According to the CDC, the two age groups at greatest risk for TBI are ages 0-4 and 15-19. Among children ages 0 to 14 years, each year TBI results in an estimated: 2,685 deaths; 37,000 hospitalizations; and 435,000 emergency department visits.
• Approximately 1,300 U.S. children experience severe or fatal brain trauma from child abuse every year.
• An estimated 5.4 million Americans have Alzheimer’s disease (AD). Today, someone in America develops AD every 68 sec-onds. By 2050, there is expected to be one new case of AD every 33 seconds, or nearly a million new cases per year, and AD prevalence is projected to be 11 million to 16 million.
• AD is the sixth leading cause of death in the United States and the fifth leading cause of death in Americans age 65 and older.
selected facts about neurological disorders
Medicines in Development neurological disorders 20138
Epilepsy5
Headache
Huntington’s Disease9
Genetic Disorders6
• epilepsy affects nearly 3 million Americans. Epilepsy is the fourth most common neurological disorder in the United States after migraine, stroke, and Alzheimer’s disease. And it costs society $17.6 billion in direct and indirect costs.
• epilepsy strikes most often among the very young and the very old, although anyone can develop the disorder at any age. In this country, it affects more than 300,000 children under the age of 15—more than 90,000 of whom have seizures that cannot be adequately treated.
• The number of epilepsy cases in the elderly is climbing as the baby boom generation reaches retirement age. More than 300,000 adults age 65 and above have the condition.
• Headaches are the most prevalent neurological disorders and among the most frequent symptoms seen in general practice—50 percent of the general population have headaches during any given year, and more than 90 percent report a lifetime history of headache.7
• Chronic headache (a headache that occurs 15 or more days per month) affects 3 percent of the general population, and those people are the most severely disabled.7
• More than 37 million Americans suffer from migraine, with women being affected three times more often than men. This vascular headache is most commonly experienced between the ages of 15 and 55, and 70 percent to 80 percent of suffer-ers have a family history of migraine.8
• The financial cost of headache arises partly from direct treatment costs, but much more from loss of work time and produc-tivity. The annual U.S. direct medical costs attributable to migraine were estimated at $1 billion in 1999.7
• More than 15,000 Americans have Huntington’s disease (HD). At least 150,000 others have a 50 percent risk of develop-ing the disease, and thousands more of their relatives live with the possibility that they, too, might develop HD.
• More than 6,000 known genetic disorders account for a significant portion of human disease and conditions and can present themselves in several different ways, such as Down syndrome, spina bifida, and sickle cell anemia.
• Up to 4 percent of the approximately 4 millon babies born each year have a genetic disease or major birth defect. More than 20 percent of infant deaths are caused by birth defects or genetic conditions (e.g., congenital heart defects, abnormalities of the nervous system, or chromosomal abnormalities).
• Approximately 10 percent of all adults and 30 percent of children in hospitals are there due to genetically-related problems.
selected facts about neurological disorders
Medicines in Development neurological disorders 2013 9
selected facts about neurological disorders
Spasticity15
Parkinson’s Disease
Pain12
• spasticity is a common finding in multiple sclerosis (MS), stroke, traumatic brain injury (TBI), cerebral palsy (CP), and spinal cord injury (SCI). Within those patient populations, spasticity occurs at a variable rate. Studies have shown that spasticity affects between 37 percent and 78 percent of people with MS, 40 percent of those with SCI, approximately 35 percent of those with stroke, more than 90 percent with CP, and approximately 50 percent of patients with TBI.
• In the United States, 50,000-60,000 new cases of Parkinson’s disease (PD) are diagnosed each year, adding to the 1 million people who currently have PD. The U.S. Centers for Disease Control and Prevention rated complications from Parkinson’s disease as the 14th leading cause of death in the United States.13
• Men are one and a half times more likely to have Parkinson’s than women.14
• The combined direct and indirect costs of Parkinson’s, including treatment, Social Security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the United States. Medication costs for an individual person with PD average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient.14
• In 2011, at least 100 million adult Americans had common chronic pain conditions.
• Recent Centers for Disease Control and Prevention (CDC) and National Center for Health Statistics (NCHS) data suggest sub-stantial rates of pain from various causes and that most people in chronic pain have multiple sites of pain. For U.S. adults report-ing pain, causes include: severe headache or migraine (16.1 percent), low back pain (28.1 percent), neck pain (15.1 percent), knee pain (19.5 percent), shoulder pain (9.0 percent), finger pain (7.6 percent), and hip pain (7.1 percent).
• Pain is a significant public health problem that costs society at least $560-$635 billion annually (an amount equal to about $2,000.00 for everyone living in the United States).
Muscular Dystrophy10
Multiple Sclerosis11
• The incidence rates of muscular dystrophies (MD) vary depending on the specific type. Duchenne MD is the most com-mon MD and is sex-linked, with an inheritance pattern of 1 case per 3,500 live male births. Becker MD is the second most common form, with an incidence of 1 case per 30,000 live male births. Other types of MD are rare. For example, limb-girdle dystrophy occurs in only 1.3 percent of patients with MDs.
• Some 350,000 to 500,000 patients suffer from multiple sclerosis (Ms) in the United States. Most cases are diagnosed between 20 and 50 years.
Medicines in Development neurological disorders 201310
selected facts about neurological disorders
Sources:
1. Alzheimer’s Association, www.alz.org
2. ALS Association, www.alsa.org
3. Brain Injury Association of America, www.biausa.org
4. American Brain Tumor Association, www.abta.org
5. Epilepsy Foundation, www.epilepsyfoundation.org
6. NetWellness from Case Western Reserve University, Ohio State University and University of Cincinnati, www.netwellness.org
7. International Association for the Study of Pain, www.iasp-pain.org
8. National Headache Foundation, www.headaches.org
9. National Institute of Neurological Disorders and Stroke, www.ninds.nih.gov
10. E-Medicine, www.emedicine.medscape.com
11. Multiple Sclerosis Foundation, www.msfocus.org
12. The American Academy of Pain Medicine, www.painmed.org
13. National Parkinson Foundation, www.parkinson.org
14. Parkinson Disease Foundation, www.pdf.org
15. Medscape, www.medscape.org
16. National Spinal Cord Injury Statistical Center, www.nscisc.uab.edu
17. American Heart Association, www.heart.org/advocacy
Spinal Cord Injury16
Stroke17
• The estimated annual incidence of spinal cord injury (sCi), not including those who die at an accident scene, is approximate-ly 12,000 new cases each year. The estimated number of people living today with SCI ranges from 238,000 to 332,000.
• The costs for those living with sCi vary greatly according to injury severity. For example, the lifetime direct medical costs are more than $4.6 million for someone with high quadriplegia injured at age 25, compared with the more than $1.5 million it will cost someone injured at the same age who has incomplete motor functions.
• stroke is the nation’s fourth leading killer and a leading cause of long-term disability. Each year, about 795,000 people suf-fer a stroke. On average, someone in the United States has a stroke every 40 seconds, and every 4 minutes someone dies from one.
• Deaths from ischemic stroke, the most common type, are predicted to nearly double between 2000 and 2032. Conserva-tive estimates forecast that ischemic stroke alone will cost the United States $2.2 trillion from 2005 to 2050.
• The direct and indirect costs of stroke in the United States for 2009 were $38.6 billion, with an average per person expen-diture of $6,018.
Medicines in Development neurological disorders 2013 11
medicines in development for neurological disorders
*For more information about a specific medicine or company in the report, please use the website provided.
Alzheimer’s Disease
Product Name Sponsor Indication Development Phase*
AAB-003/PF-05236812(beta-amyloid protein inhibitor mAB)
Janssen Alzheimer ImmunotherapySouth San Francisco, CAPfizerNew York, NY
Alzheimer’s disease Phase Iwww.janssenrnd.comwww.pfizer.com
ABT-126(alpha-7-NNR antagonist)
AbbVieNorth Chicago, IL
Alzheimer’s disease Phase IIwww.abbvie.com
ABT-288(neurotransmitter receptor modulator)
AbbVieNorth Chicago, IL
Alzheimer’s disease Phase II completedwww.abbvie.com
ABT-384 AbbVieNorth Chicago, IL
Alzheimer’s disease(see also other)
Phase II completedwww.abbvie.com
ABT-957(calpain inhibitor)
AbbVieNorth Chicago, IL
Alzheimer’s disease Phase Iwww.abbvie.com
AC-1204(glucose stimulant)
Accera Broomfield, CO
mild to moderate Alzheimer’s disease Phase II/IIIwww.accerapharma.com
AD02 vaccine (amyloid-beta protein inhibitor)
AffirisVienna, AustriaGlaxoSmithKlineRsch. Triangle Park, NC
Alzheimer’s disease Phase IIwww.affiris.comwww.gsk.com
AD03 vaccine (amyloid-beta protein inhibitor)
AffirisVienna, AustriaGlaxoSmithKlineRsch. Triangle Park, NC
Alzheimer's disease Phase Iwww.affiris.comwww.gsk.com
APH-0703(protein kinase C stimulant)
Aphios CorporationWoburn, MA
Alzheimer’s disease Phase I/IIwww.aphios.com
ARC029(nilvadipine)
Archer PharmaceuticalsSarasota, FL
Alzheimer’s disease Phase I/IIwww.archerpharma.com
ARC031(soluble amyloid reducing/clearing agent)
Archer PharmaceuticalsSarasota, FL
Alzheimer’s disease Phase Iwww.archerpharma.com
ASP0777 Astellas Pharma USNorthbrook, IL
Alzheimer’s disease Phase Iwww.astellas.com
Medicines in Development neurological disorders 201312
medicines in development for neurological disorders
Alzheimer’s Disease
Product Name Sponsor Indication Development Phase
AVN 101(serotonin 5-HT6 receptor antagonist)
Avineuro PharmaceuticalsSan Diego, CA
Alzheimer’s disease Phase IIwww.avineuro.com
AVN 322(serotonin 6 receptor antagonist)
Avineuro PharmaceuticalsSan Diego, CA
Alzheimer’s disease Phase Iwww.avineuro.com
AVN 397 Avineuro PharmaceuticalsSan Diego, CA
Alzheimer’s disease Phase IIwww.avineuro.com
AVP-923(dextromethorphan/quinidine fixed-dose combination)
Avanir PharmaceuticalsAliso Viejo, CA
agitation in Alzheimer’s disease(see also pain)
Phase IIwww.avanir.com
AZD1446(alpha4/beta2 neuronal nicotinicreceptor agonist)
AstraZenecaWilmington, DETargaceptWinston-Salem, NC
Alzheimer’s disease Phase Iwww.astrazeneca.comwww.targacept.com
AZD2184(PET enhancer)
Navidea PharmaceuticalsDublin, OH
Alzheimer’s disease (diagnosis) Phase Iwww.navidea.com
AZD2995(PET enhancer)
Navidea PharmaceuticalsDublin, OH
Alzheimer’s disease (diagnosis) Phase Iwww.navidea.com
AZD3293(beta secretase)
Astex PharmaceuticalsDublin, CAAstraZenecaWilmington, DE
Alzheimer’s disease Phase Iwww.astx.comwww.astrazeneca.com
AZD5213(histamine-3 receptor antagonist)
AstraZenecaWilmington, DE
Alzheimer’s disease Phase IIwww.astrazeneca.com
BACE inhibitor Janssen PharmaceuticalsTitusville, NJShionogiFlorham Park, NJ
Alzheimer’s disease Phase Iwww.janssenpharmaceuticalsinc.comwww.shionogi.com
BAN2401(amyloid beta-protein inhibitor)
EisaiWoodcliff Lake, NJ
early stage Alzheimer’s disease Phase IIwww.eisai.com
BIIB037(human anti-amyloid beta mAb)
Biogen IdecWeston, MA
Alzheimer’s disease Phase Iwww.biogenidec.com
bisnorcymserine(BNC)
QR PharmaBerwyn, PA
Alzheimer’s disease Phase Iwww.qrpharma.com
BMS-241027(microtubule stabilizer)
Bristol-Myers SquibbPrinceton, NJ
Alzheimer’s disease Phase Iwww.bms.com
Medicines in Development neurological disorders 2013 13
Alzheimer’s Disease
Product Name Sponsor Indication Development Phase
CAD106(amyloid beta-protein inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
Alzheimer’s disease Phase IIwww.novartis.com
CERE-110(AAV-NGF)
CeregeneSan Diego, CA
Alzheimer’s disease Phase IIwww.ceregene.com
crenezumab(anti-amyloid-beta mAb)
GenentechSouth San Francisco, CA
Alzheimer’s disease Phase IIwww.gene.com
davunetide intranasal Allon TherapeuticsVancouver, Canada
Alzheimer’s disease(see also Parkinson’s, other)
Phase IIwww.allontherapeutics.com
donepezil/memantine extended release(fixed-dose combination)
Adamas PharmaceuticalsEmeryville, CAForest LaboratoriesNew York, NY
moderate to severe Alzheimer’s disease
Phase IIwww.adamaspharma.comwww.frx.com
DSP-8658(PPAR alpha/gamma agonist)
Sunovion PharmaceuticalsMarlborough, MA
Alzheimer’s disease Phase Iwww.sunovion.com
E2212(amyloid precursor proteinsecretase modulator)
EisaiWoodcliff Lake, NJ
Alzheimer’s disease Phase I completedwww.eisai.com
E2609(BACE1 protein inhibitor)
EisaiWoodcliff Lake, NJ
Alzheimer’s disease Phase Iwww.eisai.com
ELND005 Speranza TherapeuticsDublin, Ireland
neuropsychiatric symptoms in Alzheimer’s disease(Fast Track)
Phase II
EVP-0962(gamma secretase modulator)
EnVivo PharmaceuticalsWatertown, MA
Alzheimer’s disease Phase IIwww.envivopharma.com
EVP-6124(alpha7 nicotinic acetylcholine receptor agonist)
EnVivo PharmaceuticalsWatertown, MA
Alzheimer’s disease Phase IIwww.envivopharma.com
Exebryl-1® amyloid-beta-protein/tau protein inhibitor
ProteoTechKirkland, WA
Alzheimer’s disease Phase Iwww.proteotech.com
F-18 T808(PET imaging)
Siemens Medical SolutionsMalvern, PA
Alzheimer’s disease (diagnosis) Phase 0www.usa.healthcare.siemens.com
F18-florbetaben(molecular imaging agent)
IBA MolecularDulles, VAPiramal HealthcareMumbai, India
Alzheimer’s disease (diagnosis) application submittedwww.iba-molecular.comwww.piramal.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 201314
Alzheimer’s Disease
Product Name Sponsor Indication Development Phase
F18-flutemetamol(PET imaging agent)
GE HealthcareWaukesha, WI
Alzheimer’s disease (diagnosis) application submittedwww.gehealthcare.com
gantenerumab (RG1450)
RocheNutley, NJ
early stage Alzheimer’s disease Phase II/IIIwww.roche.com
GM6(peptide therapeutic)
Genervon BiopharmaceuticalsPasadena, CA
Alzheimer’s disease(see also amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s, spinal cord injury, stroke)
Phase Iwww.genervon.com
GSK2647544(Lp-PLA2 inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
Alzheimer’s disease Phase Iwww.gsk.com
GSK2981710(medium chain triglycerides)
GlaxoSmithKlineRsch. Triangle Park, NC
Alzheimer’s disease Phase Iwww.gsk.com
HPP-854(BACE1 inhibitor)
High Point PharmaceuticalsHigh Point, NC
Alzheimer’s disease Phase Iwww.highpointpharma.com
JNJ-54861911 Janssen Research & DevelopmentRaritan, NJ
Alzheimer’s disease Phase Iwww.janssenrnd.com
KU-046(amyloid beta-protein modulator)
Kareus TherapeuticsLa Chaux-de-Fonds, Switzerland
Alzheimer’s disease Phase Iwww.kareustherapeutics.com
LMTX(TRx-0238)
TauRx PharmaceuticalsSingapore
Alzheimer’s disease, frontotemporal dementia
Phase IIIwww.taurx.com
Lu AE58054(5-HT6 receptor antagonist)
LundbeckDeerfield, ILOtsuka America PharmaceuticalRockville, MD
Alzheimer’s disease (cognition) Phase IIwww.lundbeck.comwww.otsuka.com
LY2886721(beta secretase inhibitor)
Eli LillyIndianapolis, IN
Alzheimer’s disease(slow disease progression)
Phase Iwww.lilly.com
LY3002813(biological)
Eli LillyIndianapolis, IN
Alzheimer’s disease Phase Iwww.lilly.com
Lym Pro®
neurotrophic factor companion diagnostic
Amarantus BioSciencesSunnyvale, CA
Alzheimer’s disease (diagnosis) Phase IIwww.amarantus.com
MK-8931(BACE1 protein inhibitor)
MerckWhitehouse Station, NJ
Alzheimer’s disease Phase II/IIIwww.merck.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 2013 15
Alzheimer’s Disease
Product Name Sponsor Indication Development Phase
MSDC-0160(mTOT modulator insulin sensitizer)
Metabolic Solutions Development CompanyKalamazoo, MI
Alzheimer’s disease Phase IIwww.msdrx.com
NAV4694(fluorine-18 labeled precisionradiopharmaceutical)
Navidea BiopharmaceuticalsDublin, OH
Alzheimer’s disease (diagnosis) Phase IIwww.navidea.com
NAV5001(123I-labelled imaging agent)
Navidea BiopharmaceuticalsDublin, OH
dementia with Lewy bodies (diagnosis)(see also Parkinson’s)
Phase IIwww.navidea.com
NIC5-15(amyloid precursor proteinsecretase inhibitor)
HumaneticsMinneapolis, MN
Alzheimer’s disease Phase IIwww.humaneticscorp.com
PF-05212377(SAM-760)
PfizerNew York, NY
Alzheimer’s disease Phase IIwww.pfizer.com
pioglitazone companion diagnostic Takeda Pharmaceuticals U.S.A.Deerfield, ILZinfandel PharmaceuticalsChapel Hill, NC
Alzheimer’s disease (diagnosis) Phase Iwww.takeda.com
Posiphen®
R-phenserineQR PharmaBerwyn, PA
Alzheimer’s disease, mild cognitive impairment(see also Parkinson’s)
Phase IIwww.qrpharma.com
RG1577(MAO-B inhibitor)
RocheNutley, NJ
Alzheimer’s disease Phase IIwww.roche.com
RG7129(BACE1 protein inhibitor)
RocheNutley, NJ
Alzheimer’s disease Phase Iwww.roche.com
rilapladib(Lp-PLA2 inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
Alzheimer’s disease Phase IIwww.gsk.com
RVX-208(BET protein inhibitor)
ResverlogixCalgary, Canada
Alzheimer’s disease Phase Iwww.resverlogix.com
SAR110894(H3 antagonist)
Sanofi USBridgewater, NJ
Alzheimer’s disease Phase IIwww.sanofi.com
SAR228810(anti-protofibrillar AB mAb)
Sanofi USBridgewater, NJ
Alzheimer’s disease Phase Iwww.sanofi.com
SB742457(5HT6 antagonist)
GlaxoSmithKlineRsch. Triangle Park, NC
Alzheimer’s disease Phase IIwww.gsk.com
Medicines in Development for Neurological Disorders
Medicines in Development Neurological Disorders 201316
Alzheimer’s Disease
Product Name Sponsor Indication Development Phase
sGC 1061(nomethiazole)
sGC PharmaWellesley, MA
Alzheimer’s disease Phase Iwww.sgcpharma.com
solanezumab (amyloid-beta protein inhibitor)
Eli LillyIndianapolis, IN
mild Alzheimer’s disease Phase IIIwww.lilly.com
ST101 Sonexa TherapeuticsSan Diego, CA
Alzheimer’s disease Phase IIwww.sonexa.com
T3D-959(dual PPAR agonist)
T3D TherapeuticsRsch. Triangle Park, NC
Alzheimer’s disease Phase I completedwww.t3dtherapeutics.com
T-817MA Toyama ChemicalTokyo, Japan
Alzheimer’s disease Phase IIwww.toyama-chemical.co.jp
TC-1734(ispronicline)
TargaceptWinston-Salem, NC
Alzheimer’s disease Phase IIwww.targacept.com
TC-5619 (alpha7nAChR)
TargaceptWinston-Salem, NC
Alzheimer’s disease Phase Iwww.targacept.com
TD-8954(5-HT4 agonist)
TargaceptWinston-Salem, NC
Alzheimer’s disease Phase Iwww.targacept.com
TTP488 Transtech PharmaHigh Point, NC
Alzheimer’s disease(Fast Track)
Phase IIwww.ttpharma.com
TTP4000 Transtech PharmaHigh Point, NC
Alzheimer’s disease Phase Iwww.ttpharma.com
V950 vaccine MerckWhitehouse Station, NJ
Alzheimer’s disease Phase Iwww.merck.com
vanutide cridificar(ACC-001/PF-05236806)
Janssen Alzheimer ImmunotherapySouth San Francisco, CAPfizerNew York, NY
Alzheimer’s disease Phase IIwww.janimm.comwww.pfizer.com
VI-1121 VIVUSMountain View, CA
Alzheimer’s disease Phase IIwww.vivus.com
XEL 001HP(transdermal patch)
Xel PharmaceuticalsDraper, UT
Alzheimer’s disease Phase Iwww.xelpharmaceuticals.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 2013 17
Amyotrophic Lateral Sclerosis
Product Name Sponsor Indication Development Phase
arimoclomol(Orphan Drug)
ALS AssociationWashington, DCOrphazymeCopenhagen, DenmarkUniversity of MiamiMiami, FL
amyotrophic lateral sclerosis (ALS)(Fast Track)
Phase II/IIIwww.orphazyme.com
GM6(peptide therapeutic)
Genervon BiopharmaceuticalsPasadena, CA
ALS (Fast Track) (see also Alzheimer’s, multiple sclerosis, Parkinson’s, spinal cord injury, stroke)
Phase IIwww.genervon.com
NP001(macrophage regulator)
Neuraltus PharmaceuticalsPalo Alto, CA
ALS Phase IIwww.neuraltus.com
NSI-566(stem cell therapy) (Orphan Drug)
NeuralstemRockville, MD
ALS Phase IIwww.neuralstem.com
NurOwn™GDNF-producing adult stem cell therapy(Orphan Drug)
BrainStorm Cell TherapeuticsNew York, NY
ALS Phase IIwww.brainstorm-cell.com
ozanezumab(NOGO-A mAb)
GlaxoSmithKlineRsch. Triangle Park, NC
ALS Phase IIwww.gsk.com
stem cell therapy TCA Cellular TherapyCovington, LA
ALS(see also spinal cord injury)
Phase Iwww.tcacellulartherapy.com
tirasemtiv(Orphan Drug)
CytokineticsSouth San Francisco, CA
ALS (Fast Track)
Phase IIwww.cytokinetics.com
Attention-Deficit/Hyperactivity Disorder
Product Name Sponsor Indication Development Phase
AR08(adrenergic receptor agonist)
Arbor PharmaceuticalsAtlanta, GA
attention-deficit/hyperactivity disorder (ADHD)
Phase IIwww.arborpharma.com
COL-171(sustained release)
Collegium PharmaceuticalsCumberland, RI
ADHD in clinical trialswww.collegiumpharma.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 201318
Attention-Deficit/Hyperactivity Disorder
Product Name Sponsor Indication Development Phase
d-amphetamine transdermal(ATS)
Noven PharmaceuticalsMiami, FL
ADHD Phase IIwww.noven.com
EB-1020(triple reuptake inhibitor)
Neurovance (Euthymics)Cambridge, MA
ADHD Phase Iwww.euthymics.com
edivoxetine(norepinephrine reuptake inhibitor)
Eli LillyIndianapolis, IN
ADHD (pediatric) Phase II/IIIwww.lilly.com
eltoprazine(serotonin 1A/1B partial agonist)
PsychoGenicsTarrytown, NY
ADHD (adults) Phase IIwww.psychogenics.com
HDL-100(amphetamine modified release)
Highland TherapeuticsToronto, Canada
ADHD Phase Iwww.highlandtherapeutics.com
HDL-200(methylphenidate modified-release)
Highland TherapeuticsToronto, Canada
ADHD Phase Iwww.highlandtherapeutics.com
KP106(d-amphetamine prodrug)
KemPharmNorth Liberty, IA
ADHD Phase I completedwww.kempharm.com
KRL-401 Krele Pharmaceuticals(TONIX Pharmaceuticals)New York, NY
ADHD in clinical trialswww.krele.com
methylphenidate extended release
Purdue PharmaStamford, CTRhodes PharmaCoventry, RI
ADHD Phase IIIwww.purduepharma.comwww.rhodespharma.com
NT0202(amphetamine controlled release)
Neos TherapeuticsGrand Prairie, TX
ADHD application submittedwww.neostx.com
NWP09(methylphenidate extended-release chewable tablets)
PfizerNew York, NY
ADHD Phase III completedwww.pfizer.com
OPC-34712(brexpiprazole)
LundbeckDeerfield, ILOtsuka America PharmaceuticalRockville, MD
ADHD (adults) Phase IIwww.lundbeck.comwww.otsuka.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 2013 19
Attention-Deficit/Hyperactivity Disorder
Product Name Sponsor Indication Development Phase
ORADUR®-ADHD(sustained-release oral gel)
DURECT Cupertino, CA
ADHD Phase Iwww.durect.com
SEP-225289(triple reuptake inhibitor)
Sunovion PharmaceuticalsMarlborough, MA
ADHD Phase IIwww.sunovion.com
SPN-810(molindone)
Supernus PharmaceuticalsRockville, MD
impulsive aggression in ADHD (pediatric)
Phase II completedwww.supernus.com
SPN-812(norepinephrine uptake inhibitor)
Supernus PharmaceuticalsRockville, MD
ADHD Phase II completedwww.supernus.com
TD-9855(monoamine reuptake inhibitor)
TheravanceSouth San Francisco, CA
ADHD Phase IIwww.theravance.com
Brain Injury
Product Name Sponsor Indication Development Phase
BHR-100(intravenous progesterone infusion) (Orphan Drug)
BHR PharmaHerndon, VA
traumatic brain injury(Fast Track)
Phase IIIwww.bhr-pharma.com
ciclosporin intravenous (Orphan Drug)
Maas BiolabAlbuquerque, NMNeuroVive PharmaceuticalLund, Sweden
traumatic brain injury Phase Iwww.maasbiolab.comwww.neurovive.com
methamphetamine intravenous Sinapis PharmaJacksonville, FL
traumatic brain injury(see also stroke)
Phase I completedwww.sinapispharma.com
NNZ-2566(cytokine inhibitors/neuropeptide receptor modulator)
Neuren PharmaceuticalsBethesda, MD
traumatic brain injury(Fast Track)(see also other)
Phase IIwww.neurenpharma.com
NTx-428®
cell differentiation, nerve growth factor and stem cell stimulant
Stem Cell TherapeuticsToronto, Canada
traumatic brain injury Phase IIwww.stemcellthera.com
Oxycyte®
perfluorocarbon oxygen carrierOxygen BiotherapeuticsMorrisville, NC
traumatic brain injury Phase IIwww.oxybiomed.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 201320
Brain Injury
Product Name Sponsor Indication Development Phase
RP-1127(glibenclamide)
Remedy PharmaceuticalsNew York, NY
moderate to severe traumatic brain injury(see also stroke)
Phase IIwww.remedypharmaceuticals.com
SAR127963(P75 receptor antagonist)
Sanofi USBridgewater, NJ
traumatic brain injury Phase Iwww.sanofi.com
Brain Tumors
Product Name Sponsor Indication Development Phase
8H9 mAb United TherapeuticsSilver Spring, MD
metastatic brain cancer Phase Iwww.unither.com
ABT-414(EGFR antagonist)
AbbVieNorth Chicago, IL
glioblastoma Phase Iwww.abbvie.com
AEE788(multiple tyrosine kinase inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
glioblastoma Phase I/IIwww.novartis.com
afatinib(ErbB tyrosine kinase inhibitor)
Boehringer Ingelheim PharmaceuticalsRidgefield, CT
glioblastoma Phase I/IIwww.boehringer-ingelheim.com
AMG 595(anti-EGFRvIII antibody-drug conjugate)
AmgenThousand Oaks, CA
anaplastic astrocytoma, glioblastoma
Phase Iwww.amgen.com
ANG1005(paclitaxel prodrug)
AngioChemMontreal, Canada
glioma Phase Iwww.angiochem.com
ARC 100(tubulin polymerisation inhibitor)
Archer BiosciencesNew York, NY
recurrent glioblastoma
--------------------------------------medulloblastoma, recurrent neuroblastoma
Phase IIwww.archerbiosciences.com-----------------------------------------Phase I/IIwww.archerbiosciences.com
AT-101(Bcl-2 inhibitor)
Ascenta TherapeuticsMalvern, PA
glioblastoma Phase IIwww.ascenta.com
Avastin®
bevacizumabGenentechSouth San Francisco, CA
first-line glioblastoma Phase IIIwww.gene.com
Azedra™iobenguane I-131(Orphan Drug)
Progenics PharmaceuticalsTarrytown, NY
neuroblastoma (pediatric) (Fast Track)
Phase IIwww.progenics.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 2013 21
Brain Tumors
Product Name Sponsor Indication Development Phase
BKM120(PI3K inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
glioblastoma Phase Iwww.novartis.com
ch14.18 mAb(Orphan Drug)
United TherapeuticsSilver Spring, MD
neuroblastoma Phase IIIwww.unither.com
cilengitide(Orphan Drug)
EMD SeronoRockland, MA
glioblastoma Phase IIIwww.emdserono.com
cilengitide companion diagnostic EMD SeronoRockland, MAMDxHealthIrvine, CA
glioblastoma (diagnosis) Phase IIIwww.emdserono.comwww.mdxhealth.com
cintredekin besudotox(IL13-PE38QQR)(Orphan Drug)
INSYS TherapeuticsChandler, AZNational Institute of Neurological Disorders and StrokeBethesda, MD
glioma(Fast Track)
Phase Iwww.insysrx.com
CLR 1404 I-124(PET imaging)
Novelos TherapeuticsMadison, WI
brain tumor (diagnosis) Phase I/IIwww.novelos.com
Cotara®
(iodine-131 radiolabeled TNT mAb)(Orphan Drug)
Peregrine PharmaceuticalsTustin, CA
recurrent glioblastoma(Fast Track)
Phase IIwww.peregrineinc.com
crenolanib(receptor tyrosine kinase inhibitor) (Orphan Drug)
AROG PharmaceuticalsDallas, TX
glioma (pediatric) Phase Iwww.arogpharma.com
dacomitinib (PF-00299804)
PfizerNew York, NY
glioblastoma Phase IIwww.pfizer.com
DCVax®-Braindendritic cell vaccine(Orphan Drug)
Northwest BiotherapeuticsBethesda, MD
glioblastoma Phase IIIwww.nwbio.com
DNX-2401(cell death stimulant)
DNAtrixHouston, TX
glioblastoma Phase Iwww.dnatrix.com
E7080(lenvatinib)
EisaiWoodcliff Lake, NJ
glioma Phase IIwww.eisai.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 201322
Brain Tumors
Product Name Sponsor Indication Development Phase
eflornithine(CPP-1X)
Cancer Prevention PharmaceuticalsTucson, AZ
neuroblastoma Phase IIwww.canprevent.com
ETS2101(synthetic terpene-based cannabinoid)
e-TherapeuticsOxfordshire, United KingdomUniversity of CaliforniaSan Diego, CA
glioma Phase Iwww.etherapeutics.co.uk
F18-ML-10(molecular imaging agent)
IBA MolecularDulles, VAAposensePetach-Tikva, Israel
brain tumors (diagnosis) Phase IIwww.iba-molecular.comwww.aposense.com
firtecan pegol(Orphan Drug)
Belrose PharmaPrinceton, NJ
neuroblastoma Phase I/IIwww.belrosepharma.com
galunisertib(LY2157299)
Eli LillyIndianapolis, IN
glioblastoma
--------------------------------------newly diagnosed glioma
Phase IIwww.lilly.com-----------------------------------------Phase I/IIwww.lilly.com
GDC-0084/RG7666(PI3K inhibitor)
GenentechSouth San Francisco, CA
glioma Phase Iwww.gene.com
GliAtak™cancer gene therapy (Orphan Drug)
AdvantageneAuburndale, MA
malignant glioma Phase IIwww.advantagene.com
Glionix™belagenpumatucel-Lsubcutaneous
NovaRx San Diego, CA
glioma Phase Iwww.novarx.com
Hiltonol® poly-ICLC(Orphan Drug)
OncovirWashington, DC
glioblastoma Phase II www.oncovir.com
ICT-107(autologous dendritic cell-based vaccine)(Orphan Drug)
ImmunoCellular TherapeuticsWoodland Hills, CA
glioblastoma Phase IIwww.imuc.com
IMA950(tumor-associated peptide vaccine)
Immatics BiotechnologiesTuebingen, Germany
glioblastoma Phase Iwww.immatics.com
LDE225(SMO protein inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
medulloblastoma Phase IIIwww.novartis.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 2013 23
Brain Tumors
Product Name Sponsor Indication Development Phase
LEE011(cyclin-dependent kinase-4/6 inhibitor)
Novartis PharmaceuticalsEast Hanover, NJ
neuroblastoma Phase Iwww.novartis.com
macitentan Actelion PharmaceuticalsSouth San Francisco, CA
recurrent glioblastoma Phase Iwww.actelion.us
mibefradil Tau TherapeuticsCharlottesville, VA
recurrent glioma Phase Iwww.tautherapeutics.com
NEO100(perillyl alcohol intranasal) (Orphan Drug)
NEONC TechnologiesWoodland Hills, CA
glioblastoma in clinical trialswww.neonctech.com
neuroblastoma vaccine MabVaxSan Diego, CA
neuroblastoma Phase Iwww.mabvax.com
onartuzumab(anti-c-Met mAb)
GenentechSouth San Francisco, CA
recurrent glioblastoma Phase IIwww.gene.com
Opaxio®
paclitaxel poliglumex(Orphan Drug)
Cell TherapeuticsSeattle, WA
glioblastoma Phase IIwww.celltherapeutics.com
palbociclib(PD-0332991/CDK4-6 kinase inhibitor)
PfizerNew York, NY
Rb-positive glioblastoma Phase IIwww.pfizer.com
perifosine AEterna Zentaris Basking Ridge, NJ
glioma Phase IIwww.aezsinc.com
PLX3397 PlexxikonBerkeley, CA
glioblastoma Phase IIwww.plexxikon.com
PX-866(PI-3 kinase inhibitor)
OncothyreonSeattle, WA
glioblastoma Phase IIwww.oncothyreon.com
Reolysin®
pelareorepOncolytics BiotechCalgary, Canada
glioma Phase I/II completedwww.oncolyticsbiotech.com
rindopepimut(EGFR varient III vaccine) (Orphan Drug)
Celldex TherapeuticsNeedham, MA
first-line glioblastoma (Fast Track)--------------------------------------recurrent glioblastoma (Fast Track)
Phase IIIwww.celldextherapeutics.com-----------------------------------------Phase IIwww.celldextheraputics.com
SB-313(T-cell receptor gene stimulant)
Sangamo BiosciencesRichmond, CACity of Hope National Medical CenterDuarte, CA
glioblastoma Phase Iwww.sangamo.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 201324
Brain Tumors
Product Name Sponsor Indication Development Phase
SL-701 (dendritic cell vaccine)
Stemline TherapeuticsNew York, NY
glioma Phase I/IIwww.stemline.com
Tarceva®
erlotinibAstellas Pharma USNorthbrook, IL
recurrent ependymoma (pediatric) Phase IIIwww.astellas.com
terameprocol(intravenous)
Erimos PharmaceuticalsRaleigh, NC
glioma Phase I/IIwww.erimos.com
Toca 511/Toca FC(fluorouracil prodrug gene therapy)
TocagenSan Diego, CA
recurrent glioblastoma
--------------------------------------late-stage glioma
Phase I/IIwww.tocagen.com-----------------------------------------Phase Iwww.tocagen.com
TRC105(ENG protein inhibitor)
Tracon PharmaceuticalsSan Diego, CA
glioblastoma Phase IIwww.traconpharma.com
TSC(trans-sodium crocetinate)
Diffusion PharmaceuticalsCharlottesville, VA
glioblastoma Phase I/IIwww.diffusionpharma.com
TVI-Brain-1(cancer vaccine)
TVAX BiomedicalLenexa, KS
glioma Phase IIwww.tvaxbiomedical.com
Tykerb®
lapatinibGlaxoSmithKlineRsch. Triangle Park, NCJonsson Comprehensive Cancer CenterLos Angeles, CA
glioblastoma Phase IIwww.gsk.com
VAL-083 (Orphan Drug)
Del Mar PharmaceuticalsVancouver, Canada
glioblastoma Phase I/IIwww.delmarpharma.com
VB-111(gene therapy)
VBL TherapeuticsOr Yehuda, Israel
glioblastoma Phase I/IIwww.vblrx.com
veliparib AbbVieNorth Chicago, IL
brain metastases Phase IIwww.abbvie.com
vemurafenib RocheNutley, NJ
brain metastases Phase IIwww.roche.com
vitespen(G-100 prophage)
AgenusLexington, MA
glioma Phase IIwww.agenusbio.com
Xeloda®
capecitabineRocheNutley, NJ
glioma (pediatric) Phase IIwww.roche.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 2013 25
Epilepsy
Product Name Sponsor Indication Development Phase
Banzel®rufinamide (Orphan Drug)
EisaiWoodcliff Lake, NJ
Lennox-Gastaut syndrome (pediatric) Phase IIIwww.eisai.com
BGG492(selurampanel)
Novartis PharmaceuticalsEast Hanover, NJ
partial seizures(see also headache)
Phase II completedwww.novartis.com
brivaracetam UCBSmyrna, GA
epilepsy Phase IIIwww.ucb.com
CPP -15(GABA-aminotransferase inhibitor)(Orphan Drug)
Catalyst Pharmaceutical PartnersCoral Gables, FL
complex partial seizures, infantile spasms
Phase Iwww.catalystpharma.com
diazepam intranasal spray(Orphan Drug)
Acorda TherapeuticsArdsley, NY
acute repetitive seizures Phase IIIwww.acorda.com
DSP-0565(sodium/calcium channel blocker)
Sunovion Pharmaceuticals Marlborough, MA
epilepsy Phase Iwww.sunovion.com
ezogabine extended release GlaxoSmithKlineRsch. Triangle Park, NCValeant Pharmaceuticals North AmericaBridgewater, NJ
partial onset seizures Phase IIIwww.gsk.comwww.valeant.com
Fycompa®
perampanelEisaiWoodcliff Lake, NJ
generalized seizures
--------------------------------------partial-onset seizures (pediatric)
Phase IIIwww.eisai.com-----------------------------------------Phase IIwww.eisai.com
ganaxolone (Orphan Drug)
Marinus PharmaceuticalsNew Haven, CT
infantile spasms (infants),partial-onset seizures (adults)
Phase IIwww.marinuspharma.com
INS-001(huperzine A)
Insero HealthMiami, FL
epilepsy Phase Iwww.insero.com
I.V. carbamazepine LundbeckDeerfield, IL
epilepsy Phase IIIwww.lundbeck.com
JZP8(clonazepam intranasal)
Jazz PharmaceuticalsPalo Alto, CA
recurrent acute repetitive seizures Phase IIwww.jazzpharma.com
Lyrica®
pregabalinPfizerNew York, NY
generalized tonic clonic seizures(see also pain)
Phase IIIwww.pfizer.com
midazolam intranasal(USL261)
Upsher-Smith LaboratoriesMaple Grove, MN
acute repetitive seizures(Fast Track)
Phase IIIwww.upsher-smith.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 201326
Epilepsy
Product Name Sponsor Indication Development Phase
naluzotan(serotonin 1A receptor agonist/sigma-1 receptor antagonist)
ProximagenLondon, United Kingdom
epilepsy Phase IIwww.proximagen.com
NRL-1(diazepam intranasal)
Biotie TherapiesTurku, Finland NeuralisSan Diego, CA
epilepsy Phase I www.biotie.com
PF-04895162 PfizerNew York, NY
epilepsy Phase I completedwww.pfizer.com
Potiga™ezogabine
GlaxoSmithKlineRsch. Triangle Park, NCValeant Pharmaceuticals North AmericaBridgewater, NJ
Lennox-Gastaut syndrome, partial onset seizures(patients age 12 and older)
Phase IIIwww.gsk.comwww.valeant.com
pregabalin controlled release PfizerNew York, NY
epilepsy (adjunctive treatment)(see also pain)
Phase IIIwww.pfizer.com
Stedesa®
eslicarbazepine acetateSunovion PharmaceuticalsMarlborough, MA
partial seizures in adults(adjunctive therapy)--------------------------------------partial seizures (monotherapy)
application submittedwww.sunovion.com-----------------------------------------Phase IIIwww.sunovion.com
tonabersat(USL260)
Upsher-Smith LaboratoriesMaple Grove, MN
epilepsy Phase Iwww.upsher-smith.com
topiramate extended release(USL255)
Upsher-Smith Laboratories Maple Grove, MN
partial-onset seizures application submittedwww.upsher-smith.com
topiramate intravenous(Captisol®-enabled)
CyDex Pharmaceuticals(Ligand Pharmaceuticals)Lenexa, KS
epilepsy Phase Iwww.ligand.com
Trokendi XR™topiramate controlled release
Supernus PharmaceuticalsRockville, MD
epilepsy application submittedwww.supernus.com
Vanquix® Auto-Injectordiazepam injection
PfizerNew York, NY
acute repetitive seizures(intermittent therapy)
Phase IIIwww.pfizer.com
Vimpat®
lacosamideUCBSmyrna, GA
epilepsy (monotherapy)
--------------------------------------epilepsy in patients 2-17 years of age (adjunctive therapy), primary gener-alized tonic clonic seizures (adjunctive therapy)
Phase IIIwww.ucb.com-----------------------------------------Phase IIwww.ucb.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 2013 27
Epilepsy
Product Name Sponsor Indication Development Phase
VX-765(caspase 1 inhibitor)
Vertex PharmaceuticalsCambridge, MA
treatment-resistant partial epilepsy Phase IIwww.vrtx.com
YKP-3089 SK biopharmaceuticalsFair Lawn, NJ
epilepsy(see also pain)
Phase IIwww.skbp.com
Genetic Disorders
Product Name Sponsor Indication Development Phase
Afinitor®
everlimusNovartis PharmaceuticalsEast Hanover, NJ
seizures associated with tuberoussclerosis complex (TSC)
Phase IIIwww.novartis.com
deferiprone ApoPharmaToronto, Canada
pantothenate kinase-associated neurodegeneration
Phase IIIwww.apotex.com
ecopipam(D1 dopamine receptor antagonist)(Orphan Drug)
Psyadon PharmaceuticalsGermantown, MD
Lesch-Nyhan syndrome(see also other)
Phase IIIwww.psyadonrx.com
Gammagard Liquid™immune globulin
Baxter HealthcareDeerfield, IL
Friedreich’s ataxia Phase IIwww.baxter.com
HuCNS-SC® adult neural stem cell therapy
StemCellsNewark, CA
Pelizaeus-Merzbacher disease(see also spinal cord injury)
Phase Iwww.stemcellsinc.com
ISIS-SMNRx(antisense oligonucleotide)(Orphan Drug)
Biogen IdecWeston, MA Isis PharmaceuticalsCarlsbad, CA
spinal muscular atrophy(Fast Track)
Phase IIwww.biogenidec.comwww.isispharm.com
ISIS-TTRRx(antisense RNA modulator)(Orphan Drug)
Isis PharmaceuticalsCarlsbad, CA
familial amyloid polyneuropathy(Fast Track)
Phase II/IIIwww.isispharm.com
Lenti-D™adrenoleukodystrophy gene therapy(Orphan Drug)
Bluebird BioCambridge, MA
childhood cerebral adrenoleukodystrophy
Phase I/IIwww.bluebirdbio.com
PF-06687859(DcpS protein inhibitor) (Orphan Drug)
PfizerNew York, NY
spinal muscular atrophy Phase Iwww.pfizer.com
RG2833(HDAC inhibitor) (Orphan Drug)
RepligenWaltham, MA
Friedreich’s ataxia Phase I completedwww.repligen.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 201328
Genetic Disorders
Product Name Sponsor Indication Development Phase
tafamidis meglumine(transthyretin dissociation inhibitor)(Orphan Drug)
PfizerNew York, NY
transthyretin familial amyloid poly-neuropathy(Fast Track)
application submittedwww.pfizer.com
vatiquinone(EPI-743)(Orphan Drug)
Edison PharmaceuticalsMountain View, CA
mitochondrial myopathies
--------------------------------------Friedreich’s ataxia, Leigh’s disease
Phase II/IIIwww.edisonpharma.com-----------------------------------------Phase IIwww.edisonpharma.com
VP20629 ViroPharmaExton, PA
Friedreich’s ataxia Phase Iwww.viropharma.com
UX001 sialic acid(sialic acid extended release)
Ultragenyx PharmaceuticalsNovato, CA
hereditary inclusion body myositis Phase IIwww.ultragenyx.com
Headache
Product Name Sponsor Indication Development Phase
ALD403(CGRP inhibitor mAb)
Alder BiopharmaceuticalsBothell, WA
prevention of migraine (subcutaneous)--------------------------------------prevention of migraine(intravenous)
Phase IIwww.alderbio.com-----------------------------------------Phase Iwww.alderbio.com
AMG 334(CGRP receptor antagonist mAb)
AmgenThousand Oaks, CA
migraine Phase Iwww.amgen.com
Amrix®
cyclobenzaprine extended releaseCephalon (Teva)Frazer, PA
migraine Phase IIIwww.tevapharm.com
AP-1531 (EPH receptor antagonist)
Ariel PharmaceuticalsBroomfield, CO
migraine Phase I
AVP-825 (sumatriptan intranasal)
Avanir Pharmaceuticals Aliso Viejo, CA
migraine Phase IIIwww.avanir.com
AZ-104(Staccato® loxapine low dose)
Alexza PharmaceuticalsMountain View, CA
migraine Phase II completedwww.alexza.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 2013 29
Headache
Product Name Sponsor Indication Development Phase
BGG492(selurampanel)
Novartis PharmaceuticalsEast Hanover, NJ
migraine(see also epilepsy)
Phase IIwww.novartis.com
Botox®
onabotulinumtoxinAAllerganIrvine, CA
prevention of migraine (adolescents)(see also pain, other)
Phase IIIwww.allergan.com
CL-H1T(sumatriptan)
Charleston LaboratoriesCharleston, SC
migraine Phase IIwww.charlestonlabs.com
doxepin intranasal Winston PharmaceuticalsVernon Hills, IL
chronic daily headache Phase IIwww.winstonlabs.com
DR-105(ethinylestradiol/levonorgestrel)
Duramed Pharmaceuticals (Teva)North Wales, PA
menstrual migraine Phase II completedwww.tevapharm.com
lasmiditan(serotonin 1F receptor agonist)
CoLucid PharmaceuticalsDurham, NC
migraine Phase IIwww.colucid.com
LBR-101(CGRP mAb)
Labrys BiologicsSan Mateo, CA
prevention of chronic migraine Phase Iwww.labrysbiologics.com
Levadex®
dihydroergotamine mesilateinhalation
AllerganIrvine, CAMAP PharmaceuticalsMountain View, CA
migraine (adults) application submittedwww.allergan.com
LY2951742(calcitonin gene-related peptideantagonist mAb)
Arteaus TherapeuticsCambridge, MAEli LillyIndianapolis, IN
prevention of migraine Phase IIwww.arteaus.comwww.lilly.com
NVD-201(sumatriptan oral spray)
NovaDelBridgewater, NJ
migraine Phase IIwww.novadel.com
NXN-188(nNOS inhibitor/5-HT agonist)
NeurAxonMississauga, Canada
acute migraine Phase II completedwww.neuraxon.com
odansetron/rizatriptanfixed-dose combination
MonoSol RxWarren, NJ
migraine Phase Iwww.monosolrx.com
rizatriptan oral film IntelGenxVille St-Laurent, CanadaRedHill BiopharmaTel Aviv, Israel
migraine application submittedwww.intelgenx.comwww.redhillbio.com
RT001(botulinum toxin A topical)
Revance TherapeuticsNewark, CA
migraine Phase IIwww.revance.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 201330
Headache
Product Name Sponsor Indication Development Phase
SPRIX®
ketorolac intranasalRegency TherapeuticsShirley, NY
migraine Phase IIIwww.regencytherapeutics.com
TI-001(oxytocin intranasal)
TrigeminaMoraga, CA
chronic migraine, daily headache Phase IIwww.trigemina.com
ubrogepant(MK-1602)
MerckWhitehouse Station, NJ
migraine Phase IIwww.merck.com
zolmitriptan intranasal Shin Nippon Biomedical Laboratories USAEverett, WA
migraine Phase Iwww.snblusa.com
zucapsaicin(TRPV-1 agonist)
Winston PharmaceuticalsVernon Hills, IL
cluster headache(see also pain)
Phase IIIwww.winstonlabs.com
Huntington’s Disease
Product Name Sponsor Indication Development Phase
EX-527(SIRT1 protein inhibitor)
Siena BiotechSiena, Italy
Huntington’s disease Phase I completedwww.sienabiotech.com
GSK356278(PDE4 inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
Huntington’s disease Phase Iwww.gsk.com
OMS-824(PDE10 inhibitor)
OmerosSeattle, WA
Huntington’s disease Phase Iwww.omeros.com
PBT2(metal protein-attenuating compound)
Prana BiotechnologyParkville, Australia
Huntington’s disease Phase IIwww.pranabio.com
pridopidine (Orphan Drug)
Teva PharmaceuticalNorth Wales, PA
Huntington’s disease Phase IIIwww.tevapharm.com
RP103(mercaptamine bitartratedelayed release)
Raptor PharmaceuticalsNovato, CA
Huntington’s disease Phase II/IIIwww.raptorpharma.com
SD-809(VMAT inhibitor)
Auspex PharmaceuticalsLa Jolla, CA
Huntington’s disease(see also other)
Phase Iwww.auspexpharma.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 2013 31
Multiple Sclerosis
Product Name Sponsor Indication Development Phase
ABT-413(sphingosine-1 phosphate receptor modulator)
AbbVieNorth Chicago, IL
multiple sclerosis Phase Iwww.abbvie.com
anti-LINGO(LINGO-1-protein-inhibitor)
Biogen IdecWeston, MA
multiple sclerosis Phase IIwww.biogenidec.com
ARX424(peginterferon beta-1a)
AmbrxLa Jolla, CA
multiple sclerosis Phase Iwww.ambrx.com
ATX-MS-1467(immune tolerizing agent)
EMD SeronoRockland, MA
multiple sclerosis Phase Iwww.emdserono.com
AZ01(peginterferon beta)
AllozyneSeattle, WA
multiple sclerosis Phase Iwww.allozyne.com
BHT-3009 (DNA vaccine)
Bayhill TherapeuticsPalo Alto, CA
relapsing-remittingmultiple sclerosis
Phase II completedwww.bayhilltx.com
Copaxone®glatiramer acetate for injection(20 mg)
Teva PharmaceuticalNorth Wales, PA
multiple sclerosis application submittedwww.tevapharm.com
daclizumab AbbVieNorth Chicago, ILBiogen IdecWeston, MA
multiple sclerosis, relapsing forms Phase IIIwww.abbvie.comwww.biogenidec.com
firategrast(dual alpha4-integrin antagonist)
GlaxoSmithKlineRsch. Triangle Park, NC
multiple sclerosis Phase IIwww.gsk.com
GEH-120714(18F-labeled imaging agent)
GE HealthcareWaukesha, WI
multiple sclerosis (diagnosis) Phase Iwww.gehealthcare.com
GM6(peptide therapeutic)
Genervon BiopharmaceuticalsPasadena, CA
multiple sclerosis(see also Alzheimer’s, amyotrophic lateral sclerosis, Parkinson’s, spinal cord injury, stroke)
Phase Iwww.genervon.com
GSK239512(H3 receptor inhibitor)
GlaxoSmithKlineRsch. Triangle Park, NC
multiple sclerosis Phase IIwww.gsk.com
GSK2618960(IL-7 modulator mAb)
GlaxoSmithKlineRsch. Triangle Park, NC
multiple sclerosis Phase Iwww.gsk.com
idebenone Santhera PharmaceuticalsLiestal, SwitzerlandU.S. National Institutes of HealthBethesda, MD
primary progressive multiple sclerosis(see also other)
Phase I/IIwww.santhera.com
Medicines in Development for Neurological Disorders
Medicines in Development Neurological Disorders 201332
Multiple Sclerosis
Product Name Sponsor Indication Development Phase
imilecleucel-T Opexa TherapeuticsThe Woodlands, TX
secondary progressive multiple sclerosis(Fast Track)
Phase IIwww.opexatherapeutics.com
IR208(immunostimulant vaccine)
Immune Response BioPharmaNew York, NY
multiple sclerosis Phase IIwww.immuneresponsebiopharma.com
laquinimod Teva PharmaceuticalNorth Wales, PA
multiple sclerosis(Fast Track)
Phase IIIwww.tevapharm.com
Lemtrada™alemtuzumab
Bayer HealthCare PharmaceuticalsWayne, NJGenzymeCambridge, MA
multiple sclerosis (Fast Track)
application submittedwww.bayerpharma.comwww.genzyme.com
masitinib AB Science USAShort Hills, NJ
multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis
Phase II/IIIwww.ab-science.com
MEDI-551(anti-CD19 mAb)
MedImmuneGaithersburg, MD
multiple sclerosis Phase Iwww.medimmune.com
MOR103(GM-CSF antagonist mAb)
GlaxoSmithKlineRsch. Triangle Park, NC
multiple sclerosis Phase I/II completedwww.gsk.com
ocrelizumab(humanized anti-CD20 mAb)
Biogen IdecWeston, MAGenentechSouth San Francisco, CA
primary progressive multiple sclerosis, relapsing-remitting multiple sclerosis
Phase IIIwww.biogenidec.comwww.gene.com
ofatumumabsubcutaneous(CD20 human mAb)
Genmab USPrinceton, NJGlaxoSmithKlineRsch. Triangle Park, NC
relapsing-remitting multiple sclerosis Phase IIwww.genmab.comwww.gsk.com
ONO-4641(oral S1P receptor modulator)
EMD SeronoRockland, MA
multiple sclerosis Phase IIwww.emdserono.com
Plegridy™peginterferon beta-1a
Biogen IdecWeston, MA
multiple sclerosis, relapsing forms(Fast Track)
application submittedwww.biogenidec.com
plovamer acetate(second-generation peptide copolymer)
EMD SeronoRockland, MA
multiple sclerosis Phase Iwww.emdserono.com
Medicines in Development for Neurological Disorders
Medicines in Development Neurological Disorders 2013 33
Multiple Sclerosis
Product Name Sponsor Indication Development Phase
ponesimod Actelion PharmaceuticalsSouth San Francisco, CA
multiple sclerosis Phase II completedwww.actelion.com
rHIgM22(myelin protein stimulant mAb)
Acorda TherapeuticsArdsley, NY
multiple sclerosis Phase Iwww.acorda.com
RPC1063(S1P1 receptor agonist)
ReceptosSan Diego, CA
relapsing multiple sclerosis Phase II/IIIwww.receptos.com
RTL1000 (T-lymphocyte modulator)
Artielle ImmunoTherapeuticsSan Mateo, CA
multiple sclerosis Phase Iwww.artielle.com
Sativex®
nabiximolsGW PharmaceuticalWiltshire, United Kingdom
muscle spasticity in multiple sclerosis Phase IIwww.gwpharm.com
secukinumab(AIN457)
Novartis PharmaceuticalsEast Hanover, NJ
multiple sclerosis Phase IIwww.novartis.com
siponimod(BAF312)
Novartis PharmaceuticalsEast Hanover, NJ
multiple sclerosis Phase IIIwww.novartis.com
Trimesta™estriol succinate
Synthetic BiologicsRockville, MD
multiple sclerosis Phase IIwww.syntheticbiologics.com
TSO(trichuris suis ova/CNDO-201)
Coronado BiosciencesBurlington, MA
multiple sclerosis Phase IIwww.coronadobiosciences.com
Tysarbi®natalizumab
Biogen IdecWeston, MA
multiple sclerosis (first-line therapy) in patients negative for JCV antibodies--------------------------------------secondary-progressive multiple sclerosis
application submittedwww.biogenidec.com-----------------------------------------Phase IIIwww.biogenidec.com
VX15 (SEMA-4D mAb)
Teva Pharmaceutical North Wales, PA VaccinexRochester, NY
multiple sclerosis Phase Iwww.tevapharm.comwww.vaccinex.com
XP23829(NF-kappa B inhibitor)
XenoportSanta Clara, CA
multiple sclerosis Phase Iwww.xenoport.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 201334
Muscular Dystrophy
Product Name Sponsor Indication Development Phase
AAV1-FS344(gene therapy-delivered myostatin inhibitor)(Orphan Drug)
Milo BiotechnologyCleveland, OH
Duchenne muscular dystrophy Phase I/IIwww.milobiotechnology.com
ataluren (Orphan Drug)
PTC TherapeuticsSouth Plainfield, NJ
Duchenne muscular dystrophy(Fast Track)
Phase IIIwww.ptcbio.com
drisapersen(antisense oligonucleotide) (Orphan Drug)
GlaxoSmithKlineRsch. Triangle Park, NCProsensaLeiden, Netherlands
Duchenne muscular dystrophy Phase IIIwww.gsk.com
eteplirsen(RNA interference)
Sarepta TherapeuticsCambridge, MA
Duchenne muscular dystrophy(Fast Track)
Phase IIwww.sareptatherapeutics.com
GNE lipoplex(muscular dystrophy gene therapy)
GradalisCarrollton, TX
hereditary inclusion body myopathy
Phase Iwww.gradalisinc.com
HT-100(halofunginone)(Orphan Drug)
Halo TherapeuticsNewton, MA
Duchenne muscular dystrophy Phase I/IIwww.halotherapeutics.com
PF-06252616 PfizerNew York, NY
muscular dystrophy Phase Iwww.pfizer.com
Pain
Product Name Sponsor Indication Development Phase
ABT-639(T-type calcium channel antagonist)
AbbVieNorth Chicago, IL
diabetic neuropathy Phase IIwww.abbvie.com
ABT-652(histamine H3 receptor modulator)
AbbVieNorth Chicago, IL
diabetic neuropathy Phase IIwww.abbvie.com
AF-219(purinergic P2 receptor antagonist)
Afferent PharmaceuticalsSan Mateo, CA
osteoarthritis pain Phase IIwww.afferentpharma.com
agomelatine (NRT-31/36)
NectidPrinceton, NJ
neuropathic pain, painassociated with multiple sclerosis
Phase IIwww.nectid.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 2013 35
Pain
Product Name Sponsor Indication Development Phase
ALO-02(oxycodone/naltrexone core/abuse resistant)
PfizerNew York, NY
moderate to severe chronic pain Phase IIIwww.pfizer.com
AmiKet™amitriptyline/ketamine
EpiCeptTarrytown, NY
neuropathic pain(Fast Track)
Phase IIwww.epicept.com
ARA 290(erythropoietin receptor agonist)
Araim PharmaceuticalsYorktown, NY
diabetic neuropathy Phase IIwww.araim.org
ARC-2022(lidocaine topical gel)
Arcion TherapeuticsBaltimore, MD
postherpetic neuralgia Phase I/IIwww.arciontherapeutics.com
ARRY-797(p38 MAP kinase inhibitor)
Array BioPharmaBoulder, CO
osteoarthritis pain Phase IIwww.arraybiopharma.com
AS-3201 (ranirestat)
EisaiWoodcliff Lake, NJ
diabetic neuropathy Phase IIIwww.eisai.com
ATx08 001(PPAR-gamma agonist)
Aestus TherapeuticsEast Windsor, NJ
postherpetic neuralgia Phase IIwww.aestustherapeutics.com
AV-101(NMDA receptor antagonist)
VistaGen TherapeuticsSouth San Francisco, CA
neuropathic pain Phase Iwww.vistagen.com
AVP-786(deuterated dextromethorphan)
Avanir PharmaceuticalsAliso Viejo, CA
chronic pain Phase Iwww.avanir.com
AVP-923(dextromethorphan/quinidine fixed-dose combination)
Avanir PharmaceuticalsAliso Viejo, CA
diabetic neuropathy(see also Alzheimer’s)--------------------------------------central neuropathic pain in multiple sclerosis
Phase IIIwww.avanir.com-----------------------------------------Phase IIIwww.avanir.com
BEMA buprenorphine transmucosal BioDelivery Sciences InternationalRaleigh, NC
neuropathic pain Phase IIIwww.bdsi.com
Botox®
onabotulinumtoxinAAllerganIrvine, CA
osteoarthritis pain(see also headache, other)
Phase IIwww.allergan.com
Butrans™ Transdermal System CIIIbuprenorphine transdermal
Purdue PharmaStamford, CT
chronic pain (adolescents) Phase IIIwww.purduepharma.com
Celebrex®
celecoxibPfizerNew York, NY
chronic pain application submittedwww.pfizer.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 201336
Pain
Product Name Sponsor Indication Development Phase
clonidine topical gel BioDelivery SciencesRaleigh, NC
diabetic neuropathy(Fast Track)
Phase IIwww.bdsi.com
CNSB015(flupirtine-based pain therapy)
Relevare PharmaceuticalsMelbourne, Australia
neuropathic pain Phase I/IIwww.relevarepharma.com
COL-003(oxycodone extended release/abuse-resistant formulation)
Collegium PharmaceuticalsCanton, MA
chronic lower back pain Phase IIIwww.collegiumpharma.com
COL-172(oxymorphone extended release/abuse resistant)
Collegium PharmaceuticalsCanton, MA
chronic lower back pain(Fast Track)
Phase Iwww.collegiumpharma.com
C-peptide long-acting(CBX129801)
CebixLa Jolla, CA
diabetic neuropathy (Fast Track)
Phase IIwww.cebix.com
CR845(opioid kappa receptor agonist)
Cara TherapeuticsShelton, CT
chronic pain Phase Iwww.caratherapeutics.com
CTP-354(GABA-A receptor modulator)
Concert PharmaceuticalsLexington, MA
neuropathic pain(see also spasticity)
Phase Iwww.concertpharma.com
diclofenac nano-formulation Iroko PharmaceuticalsPhiladelphia, PA
osteoarthritis pain Phase IIIwww.iroko.com
DS-5565(CACNA2D1 protein modulator)
Daiichi SankyoParsippany, NJ
chronic pain Phase IIwww.dsi.com
Eladur®
bupivacaine transdermal(Orphan Drug)
DURECTCupertino, CA
post-herpetic neuralgia Phase IIwww.durect.com
ELI-154(oxycodone controlled release)
Elite PharmaceuticalsNorthvale, NJ
chronic pain Phase IIwww.elitepharma.com
ELI-216(oxycodone/naltrexonefixed-dose combination)
Elite PharmaceuticalsNorthvale, NJ
moderate to severe chronic pain Phase IIwww.elitepharma.com
EMA401(angiotensin-type-2 receptor antagonist)
Spinifex PharmaceuticalsSouth Yarra, Australia
postherpetic neuralgia Phase Iwww.spinifexpharma.com.au
Fentora®
fentanyl buccalCephalon (Teva)Frazer, PA
chronic pain application submittedwww.tevapharm.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 2013 37
Pain
Product Name Sponsor Indication Development Phase
filorexant(dual orexin receptor antagonist)
MerckWhitehouse Station, NJ
diabetic neuropathy Phase IIwww.merck.com
fulranumab(nerve growth factor inhibitor)
Janssen Research & DevelopmentRaritan, NJ
neuropathic pain Phase IIwww.janssenrnd.com
GRT6005(ORL-1 receptor agonist)
Forest LaboratoriesNew York, NY
pain due to osteoarthritis of the knee Phase IIwww.frx.com
hydrocodone extended release (CEP-33237)
Cephalon (Teva)Frazer, PA
chronic pain Phase IIIwww.tevapharm.com
hydromorphone intrathecal MallinckrodtHazelwood, MO
chronic pain Phase IIIwww.mallinckrodt.com
K-103-IP(COX inhibitor)
Kowa Research InstituteMorrisville, NC
arthritis pain Phase Iwww.kowaus.com
KRN5500(protein synthesis inhibitor)
DARA BiosciencesRaleigh, NC
peripheral neuropathy (Fast Track)
Phase IIwww.darabio.com
levorphanol extended release(abuse-deterrent drug delivery system)
Relmada TherapeuticsBlue Bell, PA
moderate to severe chronic pain Phase Iwww.relmada.com
Lyrica®
pregabalinPfizerNew York, NY
peripheral neuropathic pain (see also epilepsy)
Phase IIIwww.pfizer.com
mavatrep Janssen Research & DevelopmentRaritan, NJ
chronic pain Phase Iwww.janssenrnd.com
meloxicam nano-formulation Iroko PharmaceuticalsPhiladelphia, PA
osteoarthritis pain Phase IIIwww.iroko.com
NCE Eli LillyIndianapolis, IN
osteoarthritis pain Phase Iwww.lilly.com
neublastin Biogen IdecWeston, MANsGeneBallerup, Denmark
neuropathic pain Phase Iwww.biogenidec.com
NKTR-181(mu-opioid agonist)
Nektar TherapeuticsSan Francisco, CA
moderate to severe chronic pain(Fast Track)
Phase IIwww.nektar.com
Medicines in Development for Neurological Disorders
Medicines in Development Neurological Disorders 201338
Pain
Product Name Sponsor Indication Development Phase
NP-1998(capsaicin topical liquid)
Acorda TherapeuticsArdsley, NY
neuropathic pain Phase IIwww.acorda.com
NXN-462(nNOS inhibitor)
NeurAxonMississauga, Canada
postherpetic neuralgia Phase IIwww.neuraxon.com
oxycodone/naloxone controlled release(OXN)
Purdue PharmaStamford, CT
severe chronic lower back pain Phase IIwww.purduepharma.com
PA65020(aspirin 650mg/omeprazole 20mgfixed-dose combination)
POZENChapel Hill, NC
chronic pain Phase Iwww.pozen.com
Pennsaid® 2%diclofenac transdermalsecond-generation
Nuvo ResearchMississauga, Canada
osteoarthritis pain application submittedwww.nuvoresearch.com
PF-05089771(Nav1.7 sodium channel inhibitor)
PfizerNew York, NY
chronic pain Phase Iwww.pfizer.com
PF-06273340 PfizerNew York, NY
chronic pain Phase Iwww.pfizer.com
PF-06305591 PfizerNew York, NY
chronic pain Phase Iwww.pfizer.com
PLX1100(ibuprofen/phosphatidylcholine)
PLx PharmaHouston, TX
osteoarthritis pain Phase IIwww.plxpharma.com
pregabalin controlled release PfizerNew York, NY
postherpetic neuralgia(see also epilepsy)
Phase IIIwww.pfizer.com
PTI-202(abuse-resistant opioid)
Pain TherapeuticsAustin, TX
moderate to severe chronic pain Phase I completedwww.paintrials.com
PTI-721(abuse-resistant opioid)
Pain TherapeuticsAustin, TX
moderate to severe chronic pain Phase I completedwww.paintrials.com
Qutenza®
capsaicin 8% patchAstellas PharmaTokyo, JapanNeurogesXSan Mateo, CA
HIV-associated neuropathy(Fast Track)
--------------------------------------diabetic neuropathy
application submittedwww.astellas.comwww.neurogesx.com-----------------------------------------Phase IIIwww.astellas.comwww.neurogesx.com
Medicines in Development for Neurological Disorders
Medicines in Development Neurological Disorders 2013 39
Pain
Product Name Sponsor Indication Development Phase
Remoxy™oxycodone controlled release (Mu-type opioid receptor agonist/abuse resistant)
Pain TherapeuticsAustin, TXPfizerNew York, NY
moderate to severe chronic pain application submittedwww.pfizer.com
rezatomidine(alpha adrenergic receptor agonist)
ACADIA PharmaceuticalsSan Diego, CAAllerganIrvine, CA
diabetic neuropathy Phase IIwww.acadia-pharm.comwww.allergan.com
S-117957 Purdue PharmaStamford, CTShionogiFlorham Park, NJ
neuropathic pain Phase Iwww.purduepharma.comwww.shionogi.com
SAR292833/GRC15300(TRVP3 antagonist)
Glenmark PharmaceuticalsMumbai, IndiaSanofi USBridgewater, NJ
neuropathic pain, osteoarthritis pain Phase IIwww.sanofi.com
SD-254(deuterium-substituted venlafaxine analogue)
Auspex PharmaceuticalsLa Jolla, CA
neuropathic pain Phase Iwww.auspexpharma.com
SEP-228432(SRNDI inhibitor)
Sunovion PharmaceuticalsMarlborough, MA
neuropathic pain Phase Iwww.sunovion.com
SKL-NP SK biopharmaceuticalsFair Lawn, NJ
neuropathic pain Phase IIwww.skbp.com
sufentanil(transdermal delivery system)
DURECTCupertino, CA
chronic pain Phase IIwww.durect.com
TAK-428(neurotrophic factor productionaccelerator)
Takeda Pharmaceuticals InternationalDeerfield, IL
diabetic neuropathy Phase IIwww.takeda.com
TEM(senrebotase)
AllerganIrvine, CA
postherpetic neuralgia Phase IIwww.allergan.com
V116517 Purdue PharmaStamford, CT
pain due to osteoarthritis of the knee, postherpetic neuralgia
Phase IIwww.purduepharma.com
V158866 (FAAH inhibitor)
VernalisWinnersh, United Kingdom
neuropathic pain Phase IIwww.vernalis.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 201340
Pain
Product Name Sponsor Indication Development Phase
VBY-036(protease inhibitor)
VirobayMenlo Park, CA
neuropathic pain Phase Iwww.virobayinc.com
verapamil Calosyn PharmaSharon, MA
osteoarthritis pain Phase I/IIwww.calosynpharma.com
Vicodin® CRhydrocodone/paracetamolcontrolled release
AbbVieNorth Chicago, IL
back pain, osteoarthritis pain application submittedwww.abbvie.com
VM202(modified hepatocyte growth factor gene therapy)
ViroMedSeoul, South Korea
diabetic neuropathy Phase IIwww.viromed.co.kr
XEN402 Teva PharmaceuticalNorth Wales, PAXenon PharmaceuticalsBurnaby, Canada
postherpetic neuralgia Phase IIwww.tevapharm.comwww.xenon-pharma.com
YKP-509(carisbamate)
SK biopharmaceuticalsFair Lawn, NJ
neuropathic pain Phase IIwww.skbp.com
YKP-3089 SK biopharmaceuticalsFair Lawn, NJ
neuropathic pain(see also epilepsy)
Phase IIwww.skbp.com
Z160(N-type calcium channel antagonist)
ZalicusCambridge, MA
neuropathic pain, postherpetic neuralgia
Phase IIwww.zalicus.com
Z944 (T-type calcium channel antagonist)
ZalicusCambridge, MA
neuropathic pain Phase Iwww.zalicus.com
Zohydro ER™hydrocodone extended-release
ZogenixSan Diego, CA
moderate to severe chronic pain application submittedwww.zogenix.com
zucapsaicin(TRPV-1 agonist) (Orphan Drug)
Winston PharmaceuticalsVernon Hills, IL
chronic pain, postherpetic neuralgia(see also headache)
application submittedwww.winstonlabs.com
medicines in development for neurological disorders
Medicines in Development neurological disorders 2013 41
Parkinson’s Disease
Product Name Sponsor Indication Development Phase
AFQ056(mavoglurant)
Novartis PharmaceuticalsEast Hanover, NJ
drug-induced dyskinesia in Parkinson’s disease
Phase IIwww.novartis.com
AQW051(alpha7 nicotinic acetylcholinereceptor agonist)
Novartis PharmaceuticalsEast Hanover, NJ
drug-induced dyskinesiain Parkinson’s disease
Phase II completedwww.novartis.com
autologous stem cell therapy NeuroGenerationLos Angeles, CA
Parkinson’s disease Phase Iwww.neurogeneration.com
AVE-8112(PDE4 inhibitor)
Sanofi USBridgewater, NJThe Michael J. Fox Foundationfor Parkinson’s ResearchNew York, NY
Parkinson’s disease Phase Iwww.sanofi.comwww.michaeljfox.org
AZD3241(myeloperoxidase inhibitor)
AstraZenecaWilmington, DE
Parkinson’s disease Phase IIwww.astrazeneca.com
CERE-120(AAV-NTN)
CeregeneSan Diego, CA
Parkinson’s disease Phase IIwww.ceregene.com
CVT-301(levodopa inhalation)
Civitas TherapeuticsChelsea, MA
Parkinson’s disease Phase IIwww.civitastherapeutics.com
davunetide intranasal Allon TherapeuticsVancouver, Canada
Parkinson’s disease(see also Alzheimer’s, other)
Phase Iwww.allontherapeutics.com
dipraglurant(ADX48621) (immediate release)
Addex TherapeuticsGeneva, Switzerland
levodopa-induced dyskinesia in Parkinson’s disease
Phase IIwww.addextherapeutics.com
DM-1992(carbidopa/levodopa controlled-release)
Depomed, Inc.Newark, CA
Parkinson’s disease Phase IIwww.depomed.com
Duopa®
levodopa/carbidopaintestinal gel (LCIG)(Orphan Drug)
AbbVieNorth Chicago, IL
advanced Parkinson’s disease (Fast Track)
application submittedwww.abbvie.com
fipamezole (alpha-2 adrenergic receptor antagonist)
Santhera PharmaceuticalsLiestal, Switzerland
Parkinson’s disease (Fast Track)
Phase II completedwww.santhera.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 201342
Parkinson’s Disease
Product Name Sponsor Indication Development Phase
GM6(peptide therapeutic)
Genervon BiopharmaceuticalsPasadena, CA
Parkinson’s disease (see also Alzheimer’s, amyotrophic lateral sclerosis, multiple sclerosis, spinal cord injury, stroke)
Phase IIwww.genervon.com
GZ404477(AAV-hAADC gene therapy)
GenzymeCambridge, MA
Parkinson’s disease Phase Iwww.genzyme.com
HT-1067(MOA-B reversible inhibitor)
Dart NeuroScienceSan Diego, CA
Parkinson’s disease Phase Iwww.dartneuroscience.com
KW-6002(istradefylline)
Kyowa Hakko Kirin AmericaPrinceton, NJ
Parkinson’s disease application submittedwww.kyowa-kirin.com
levodopa/carbidopa extended release
IMPAX LaboratoriesHayward, CA
Parkinson’s disease application submittedwww.impaxlabs.com
NAV5001(123I-labelled imaging agent)
Navidea BiopharmaceuticalsDublin, OH
Parkinsonian disorder (diagnosis)(see also Alzheimer’s)
Phase IIIwww.navidea.com
Nurelin™ADS-5102/amantadine ER
Adamas PharmaceuticalsEmeryville, CA
levodopa-induced dyskinesiain Parkinson’s disease
Phase IIIwww.adamaspharma.com
NuroPro®
neurotrophic factor companion diagnostic
Amarantus BioSciencesSunnyvale, CA
Parkinson’s disease (diagnosis) Phase IIwww.amarantus.com
opicapone(COMT inhibitor)
BialLisbon, Portugal
Parkinson’s disease Phase Iwww.bial.com
OS-320(levodopa/carbidopa)
Osmotica PharmaceuticalWilmington, NC
Parkinson’s disease Phase IIIwww.osmoticausa.com
Posiphen®
R-phenserineQR PharmaBerwyn, PA
Parkinson’s disease(see also Alzheimer's)
Phase IIwww.qrpharma.com
PYM-50028 PhytopharmHuntingdon, United Kingdom
early stage Parkinson’s disease Phase IIwww.phytopharm.com
safinamide Newron PharmaceuticalsBresso, ItalyZambonBresso, Italy
Parkinson’s disease Phase IIIwww.newron.comwww.zambonpharma.com
tozadenant(adenosine A2A receptor antagonist)
Biotie TherapiesSouth San Francisco, CA UCBBrussels, Belgium
Parkinson’s disease Phase II/IIIwww.biotie.comwww.ucb.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 2013 43
Parkinson’s Disease
Product Name Sponsor Indication Development Phase
XP21279(dopamine receptor agonist)
XenoportSanta Clara, CA
Parkinson’s disease Phase IIwww.xenoport.com
Spasticity
Product Name Sponsor Indication Development Phase
CK-2127107 CytokineticsSouth San Francisco, CA
muscular atrophy associated with neuromuscular dysfunction, muscular weakness, and/or muscle fatigue
Phase Iwww.cytokinetics.com
CTP-354(GABA-A receptor modulator)
Concert PharmaceuticalsLexington, MA
muscle spasticity(see also pain)
Phase Iwww.concertpharma.com
Dysport®
abobotulinumtoxinAIpsen BiopharmaceuticalsBasking Ridge, NJ
focal spasticity of upper and lower limb in adults, adolescents and children
Phase IIIwww.ipsen.com
OS-440(arbaclofen extended release)
Osmotica PharmaceuticalMarietta, GA
muscle spasticity due to multiple sclerosis
Phase IIIwww.osmotica.com
SUN 09(baclofen extended release)
Sun Pharma Advanced ResearchMumbai, India
muscle spasticity due to multiple sclerosis
Phase IIIwww.sunpharma.in
Xeomin®
incobotulinumtoxinAMerz PharmaceuticalsGreensboro, NC
post-stroke spasticity Phase IIIwww.merzusa.com
Spinal Cord Injury
Product Name Sponsor Indication Development Phase
AC105(nervous system modulator)
Acorda TherapeuticsArdsley, NY
spinal cord injury(Fast Track)
Phase IIwww.acorda.com
ATI355(anti-NOGO-A mAb) (Orphan Drug)
Novartis PharmaceuticalsEast Hanover, NJ
spinal cord injury Phase Iwww.novartis.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 201344
Spinal Cord Injury
Product Name Sponsor Indication Development Phase
autologous stem cell therapy DaVinci BiosciencesCosta Mesa, CA
spinal cord injury in clinical trialswww.dvbiosciences.com
BA-210(Rho GTP-binding protein-inhibitor)(Orphan Drug)
BioAxone BioSciencesFt. Lauderdale, FL
spinal cord injury Phase IIwww.bioaxonebio.com
GM6(peptide therapeutic)
Genervon BiopharmaceuticalsPasadena, CA
spinal cord injury (see also Alzheimer’s, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s, stroke)
Phase Iwww.genervon.com
HuCNS-SC®
adult neural stem cell therapyStemCellsNewark, CA
chronic spinal cord injury(see also genetic)
Phase I/IIwww.stemcellsinc.com
NEU2000 GNT PharmaYongin, South Korea
spinal cord injury(see also stroke)
Phase I completedwww.gntpharma.com
stem cell therapy TCA Cellular TherapyCovington, LA
spinal cord injury(see also amyotrophic lateral sclerosis)
Phase Iwww.tcacellulartherapy.com
SUN13837 (FGF-receptor agonist)
Daiichi SankyoParsippany, NJ
spinal cord injury Phase IIwww.dsi.com
Stroke
Product Name Sponsor Indication Development Phase
3K3A-APC(recombinant humanactivated protein C)
ZZ BiotechHouston, TX
stroke Phase Iwww.zzbiotech.com
ALD-401(bone marrow-derived adult stem cell therapy)
CytomedixGaithersburg, MD
stroke Phase IIwww.cytomedix.com
allogeneic mesenchymal bone marrow cell therapy
Stemedica Cell TechnologiesSan Diego, CA
ischemic stroke Phase I/IIwww.stemedica.com
Ampyra®
fampridine sustained-releaseAcorda TherapeuticsArdsley, NY
post-stroke deficits (see also other)
Phase IIwww.acorda.com
Medicines in Development for Neurological Disorders
Medicines in Development Neurological Disorders 2013 45
Stroke
Product Name Sponsor Indication Development Phase
betrixaban Portola PharmaceuticalsSouth San Francisco, CA
prevention of stroke in patients with atrial fibrillation
Phase IIwww.portola.com
CNTO-0007(cell therapy)
Janssen Research & DevelopmentRaritan, NJ
stroke Phase I/IIwww.janssenrnd.com
desmoteplase LundbeckDeerfield, IL
stroke (Fast Track)
Phase IIIwww.lundbeck.com
GM6(peptide therapeutic)
Genervon BiopharmaceuticalsPasadena, CA
stroke (see also Alzheimer’s, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson’s, spinal cord injury)
Phase IIwww.genervon.com
GSK249320(myelin-associated glycoproteinmAb)
GlaxoSmithKlineRsch. Triangle Park, NC
stroke Phase IIwww.gsk.com
methamphetamine intravenous Sinapis PharmaJacksonville, FL
stroke(see also brain injury)
Phase I completedwww.sinapispharma.com
MP-124(PARP inhibitor)
Mitsubishi Tanabe Pharma AmericaJersey City, NJ
acute ischemic stroke Phase Iwww.mt-pharma.co.jp
MultiStem®
stem cell therapyAthersysCleveland, OH
stroke Phase IIwww.athersys.com
NA-1(signal transduction pathway inhibitor)
NoNOToronto, Canada
acute ischemic stroke Phase II completedwww.nonoinc.ca
NEU2000 GNT PharmaYongin, South Korea
stroke(see also spinal cord injury)
Phase I completedwww.gntpharma.com
PF-03049423 PfizerNew York, NY
stroke recovery Phase IIwww.pfizer.com
RP-1127(glibenclamide)
Remedy PharmaceuticalsNew York, NY
stroke (see also brain injury)
Phase IIwww.remedypharmaceuticals.com
SAR126119(TAFIa inhibitor)
Sanofi USBridgewater, NJ
acute ischemic stroke Phase Iwww.sanofi.com
SB623(stem cell therapy)
SanBioMountain View, CA
stroke Phase I/IIwww.san-bio.com
Medicines in Development for Neurological Disorders
Medicines in Development Neurological Disorders 201346
Stroke
Product Name Sponsor Indication Development Phase
TS01(recombinant complementC1-inactivator-protein)
Thrombolytic Science InternationalCambridge, MA
stroke Phase Iwww.tsillc.com
Other
Product Name Sponsor Indication Development Phase
18F-AV-133imaging agent
Avid RadiopharmaceuticalsPhiladelphia, PA
neurodegenerative disorders (diagnosis)
Phase I/IIwww.avidrp.com
Abilify®
aripiprazole (once-weekly)
Otsuka America PharmaceuticalRockville, MD
Tourette’s syndrome Phase IIIwww.otsuka.com
ABT-354(serotonin-6 receptor antagonist)
AbbVieNorth Chicago, IL
neurological disorders Phase Iwww.abbvie.com
ABT-384 AbbVieNorth Chicago, IL
neurological disorders(see also Alzheimer’s)
Phase I completedwww.abbvie.com
Ampyra®
fampridine sustained releaseAcorda TherapeuticsArdsley, NY
cerebral palsy(see also stroke)
Phase IIwww.acorda.com
AP-1101 Ariel PharmaceuticalsBroomfield, CO
neuroprotection against postoperative cognitive decline and memory loss in patients undergoing extracorporeal cardiopulmonary bypass
Phase II
Botox®
onabotulinumtoxinAAllerganIrvine, CA
juvenile cerebral palsy(see also headache, pain)
Phase IIIwww.allergan.com
BYM338(type II-B activin receptor modulator mAb)
Novartis PharmaceuticalsEast Hanover, NJ
inclusion body myositis Phase IIwww.novartis.com
CX1739(AMPA receptor agonist)
Cortex PharmaceuticalsGlen Rock, NJ
central sleep apnea Phase Iwww.cortexpharm.com
davunetide intranasal(Orphan Drug)
Allon TherapeuticsVancouver, Canada
progressive supranuclear palsy(Fast Track)(see also Alzheimer’s, Parkinson’s)
Phase II/IIIwww.allontherapeutics.com
Medicines in Development for Neurological Disorders
Medicines in Development neurological disorders 2013 47
Other
Product Name Sponsor Indication Development Phase
ecopipam(D1 dopamine receptor antagonist)
Psyadon PharmaceuticalsGermantown, MD
Tourette’s syndrome(see also genetic)
Phase I/IIwww.psyadonrx.com
EVP-0334(HDAC inhibitor)
EnVivo PharmaceuticalsWatertown, MA
neurodegenerative disorders Phase Iwww.envivopharma.com
Firdapse™amifampridine(Orphan Drug)
Catalyst Pharmaceutical PartnersCoral Gables, FL
Lambert-Eaton myasthenic syndrome Phase IIIwww.catalystpharma.com
Gilenya®
fingolimodNovartis PharmaceuticalsEast Hanover, NJ
chronic inflammatorydemyelinatingpolyradiculoneuropathy
Phase IIIwww.novartis.com
glycerol phenylbutyrate(Orphan Drug)
Hyperion TherapeuticsSouth San Francisco, CA
hepatic encephalopathy Phase II completedwww.hyperiontx.com
human immune globulin (subcutaneous)
CSL BehringKing of Prussia, PA
chronic inflammatory demyelinating polyradiculoneuropathy
Phase IIIwww.cslbehring.com
idebenone(Orphan Drug)
Columbia University New York, NY Santhera PharmaceuticalsLiestal, Switzerland
MELAS syndrome(see also multiple sclerosis)
Phase IIwww.santhera.com
interleukin-7 CytherisRockville, MD
progressive multifocal leukoencephalopathy
Phase IIwww.cytheris.com
IPX159 IMPAX PharmaceuticalsHayward, CA
restless legs syndrome Phase IIwww.impaxpharma.com
MK-8616 (sugammadex)
MerckWhitehouse Station, NJ
neuromuscular blockade application submittedwww.merck.com
NBI-98854(VMAT2 inhibitor)
Neurocrine BiosciencesSan Diego, CA
drug-induced dyskinesia(Fast Track)
Phase IIwww.neurocrine.com
NH001(apomorphine subcutaneous)(Orphan Drug)
NeuroHealing PharmaceuticalsWaban, MA
coma(Fast Track)
Phase IIwww.neurohealing.com
medicines in development for neurological disorders
Medicines in Development Neurological Disorders 201348
Other
Product Name Sponsor Indication Development Phase
NNZ-2566(cytokine inhibitors/neuropeptide receptor modulator)
Neuren PharmaceuticalsBethesda, MD
Rett syndrome(Fast Track)(see also brain injury)
Phase Iwww.neurenpharma.com
OCR-002(ornithine phenylacetate) (Orphan Drug)
Ocera TherapeuticsSan Diego, CA
hepatic encephalopathy in patientswith acute liver failure (iv)(Fast Track)--------------------------------------hepatic encephalopathy in patients with liver cirrhosis (oral)(Fast Track)
Phase IIwww.ocerainc.com
-----------------------------------------Phase Iwww.ocerainc.com
placulumab Cephalon (Teva)Frazer, PA
sciatica Phase I/IIwww.tevapharm.com
pomaglumetad(LY2140023 monohydrate)
Eli LillyIndianapolis, IN
CNS disorders Phase Iwww.lilly.com
SD-809(VMAT inhibitor)
Auspex PharmaceuticalsLa Jolla, CA
drug-induced dyskinesias, Tourette’s syndrome(see also Huntington’s)
Phase Iwww.auspexpharma.com
Soliris®
eculizumab (Orphan Drug)
Alexion PharmaceuticalsCheshire, CT
myasthenia gravis, severe and relaps-ing neuromyelitis optica
Phase IIwww.alxn.com
SPI-017 Sucampo PharmaceuticalsBethesda, MD
lumbar spinal stenosis Phase IIwww.sucampo.com
SPI-3608 Sucampo PharmaceuticalsBethesda, MD
spinal stenosis Phase Iwww.sucampo.com
Tardoxyl™pyridoxal phosphate
Medicure PharmaSomerset, NJ
drug-induced dyskinesia(Fast Track)
Phase IIwww.medicure.com
uridine triacetate (PN401)
Wellstat TherapeuticsGaithersburg, MD
neurodegenerative disorders Phase Iwww.wellstattherapeutics.com
vigabatrin(GABA-AT inhibitor)
Catalyst Pharmaceutical PartnersCoral Gables, FL
Tourette’s syndrome Phase I/IIwww.catalystpharma.com
Medicines in Development neurological disorders 2013 49
Glossary
Alzheimer’s disease—The most com-mon form of dementia, characterized by progressive and chronic deterioration of cognitive functions, including memory, thinking and reasoning. Early manifes-tations include forgetfulness, impaired ability to focus, and changes in mood and personality. As the disease progresses, there is a loss of computational ability, in addition to word-finding problems and dif-ficulty with ordinary activities. Ultimately, the disease leads to severe memory loss, complete disorientation, social withdrawal, loss of independence, and is fatal.
amyotrophic lateral sclerosis (Als)—Also known as Lou Gehrig’s disease, the most common of the motor neuron dis-eases, a group of rare disorders in which the nerves that control muscular activity degenerate within the brain and spinal cord causing weakness and wasting of the muscles.
application submitted—An application for marketing has been submitted by the company to the Food and Drug Admin-istration (FDA).
attention deficit/hyperactivity disorder (ADHD)—ADHD is a complex neurologi-cal impairment that results in an over-active behavior pattern and a difficulty concentrating. While it primarily affects children, a growing number of adults are being diagnosed with the disorder. Boys are affected about three times as often as girls. Children with ADHD are fidgety, impulsive, reckless, irritable, emotionally immature and sometimes aggressive. Because their attention span is short, they do not conform to orderly routine. ADHD often leads to anti-social acts and difficulty learning, although IQ is normal. No definite cause has been established, but some researchers now believe genet-ics plays a role.
cerebral palsy—A general term for disor-ders of movement and posture resulting from damage to the brain in pregnancy, during birth, in the newborn period or in early childhood.
dementia—Degeneration of central nervous functions, such as memory and
learning capacity. The natural decline of these functions with age is grossly exag-gerated in dementia.
Duchenne muscular dystrophy—An inherited disorder that involves rapidly worsening muscle weakness. Other muscular dystrophies get worse much more slowly. Duchenne’s is caused by a defective gene. Because of the way the disease is inherited, males are more likely to develop symptoms than are women.
epilepsy—Recurrent seizures—transient neurological abnormalities caused by abnormal electrical activity in the brain—or temporary alteration in one or more brain functions. Seizures are a symptom of brain dysfunction and can result from a wide variety of diseases or injury.
Fast Track—A process designed to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need. The status is assigned by the U.S. Food and Drug Administration. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious diseases. Gener-ally, determining factors include whether the drug will have an impact on such factors as survival, day-to-day function-ing, or the likelihood that the disease, if left untreated, will progress from a less severe condition to a more serious one. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially superior to existing therapy. Once a drug receives Fast Track designa-tion, early and frequent communication between the FDA and a drug company is encouraged throughout the entire drug development and review process. The frequency of communication assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.
Friedreich’s ataxia—An inherited disease that causes progressive dam-age to the nervous system resulting in symptoms ranging from gait disturbance and speech problems to heart disease. “Ataxia,” which refers to coordination
problems such as clumsy or awkward movements and unsteadiness, occurs in many different diseases and conditions.
glioblastoma multiforme—The most common and most malignant of the as-trocytomas. The tumor grows so fast that it increases pressure in the brain, produc-ing headaches, slowed thinking, and if severe enough, sleepiness and coma.
glioma—A type of brain tumor arising from the supporting glial cells within the brain. Gliomas make up about 60 percent of all primary brain tumors.
Huntington’s disease—Huntington’s chorea is an uncommon, inherited dis-ease in which degeneration of the basal ganglia (structures deep in the brain) results in chorea (rapid, jerky, involuntary movements) and dementia (progressive mental impairment).
lennox-Gastaut syndrome—Character-ized by seizures and mental retardation in infants and young children.
metastases/metastatic—Areas of sec-ondary cancer that have spread from the primary or original cancer site.
migraine—Severe headache result-ing from an abnormal dilation of blood vessels deep within the brain. It can last from two hours to several days and is often accompanied by nausea, vomiting and sensitivity to noise and/or light.
multiple sclerosis (Ms)—Progressive disease of the central nervous system in which scattered patches of the covering of nerve fibers (myelin) in the brain and spinal cord are destroyed. Symptoms range from numbness and tingling to paralysis and incontinence.
muscular dystrophy—Inherited muscu-lar disorder of unknown cause in which muscle fibers slowly degenerate. Duch-enne MD is the most common type.
myasthenia gravis—A chronic autoim-mune neuromuscular disease character-ized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis
Medicines in Development Neurological Disorders 201350
Glossary
is muscle weakness that increases during periods of activity and improves after periods of rest.
neuroblastoma—A tumor of the adrenal glands or sympathetic nervous system (the part of the nervous system respon-sible for certain automatic body func-tions, such as the control of heart rate). Neuroblastomas are the most common extracranial (outside the skull) solid tumors of childhood.
neuropathic pain—Caused by disease, inflammation, or damage to the periph-eral nerves, which connect the central nervous system (brain and spinal cord) to the sense organs, muscles, glands, and internal organs.
neuropathy—Disease, inflammation, or damage to the peripheral nerves, which connect the central nervous system to the sense organs, muscles, glands, and internal organs.
Orphan Drug—A drug to treat a disease that has a patient population of 200,000 or less, or a disease that has a patient population of more than 200,000 and a developmental cost that will not be re-covered from sales in the United States.
Parkinson’s disease—Chronic neurologic disease of unknown cause, characterized by tremors, rigidity and an abnormal gait.
Phase 0—First-in-human trials conduct-ed in accordance with FDA’s 2006 guid-ance on exploratory Investigational New Drug (IND) studies designed to speed up development of promising drugs by es-tablishing very early whether the tested compound behaves in human subjects as was anticipated from preclinical studies.
Phase I—Safety testing and pharmaco-logical profiling in humans.
Phase II—Effectiveness testing in humans.
Phase III—Extensive clinical trials in humans.
postherpetic neuralgia—A burning pain that may recur at the site of an attack of shingles months or even years after the illness.
prodrug—An inactive medicine that becomes active inside the body through metabolic processes. Prodrugs can be used to improve how a specific medi-cine is absorbed, distributed, metabo-lized or excreted.
restless legs syndrome—Restless legs syndrome is an overwhelming urge to move the legs usually caused by uncomfortable or unpleasant sensations in the legs.
spinal cord injury—Damage to the spinal cord which can cause loss of sensation, muscle weakness or paralysis.
stroke—Usually caused by atheroscle-rosis. It results in death or serious brain damage, such as paralysis or loss of speech. An ischemic stroke is caused by blocked or narrowed arteries that prevent sufficient blood and oxygen from reaching the brain.
Tourette syndrome (TS)—A neurologi-cal disorder characterized by repetitive, involuntary movements and vocalizations called tics. The early symptoms of TS are typically noticed first in childhood, with the average onset between the ages of 3 and 9. TS occurs in people from all ethnic groups; males are affected about three to four times more often than females. It is estimated that 200,000 Americans have the most severe form of TS, and as many as 1 in 100 exhibit milder and less complex symptoms such as chronic motor or vocal tics. Although TS can be a chronic condition with symptoms lasting a lifetime, most people with the condition experience their worst tic symptoms in their early teens, with improvement occurring in the late teens and continuing into adulthood.
The content of this report has been obtained through public, government and industry sources, and the Adis “R&D Insight” data-base based on the latest information. Report current as of July 18, 2013. The medicines in this report include medicines being developed by U.S. based companies conducting trials in the United States and abroad, PhRMA-member companies conducting trials in the United States and abroad, and foreign companies conducting clinical trials in the United States. The information in this report may not be comprehensive. For more specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA’s website.
A publication of PhRMA’s Communications & Public Affairs Department. (202) 835-3460
www.phrma.org | www.innovation.org | www.pparx.org
Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.
Copyright © 2013 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.
Pharmaceutical Research and Manufacturers of America • 950 F Street, NW, Washington, DC 20004
the drug discovery, development and approval process
The U.S. system of new drug approvals is perhaps the most rigorous in the world.
It takes 10-15 years, on average, for an experi-mental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development. Only five in 5,000 com-pounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.
On average, it costs a company $1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a recent study by the Tufts Center for the Study of Drug Development.
Once a new compound has been identified in the laboratory, medicines are usually developed as follows:
Preclinical Testing. A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evalu-ated for safety.
Investigational New Drug Application (IND). After completing preclinical testing, a com-pany files an IND with the U.S. Food and Drug Administration (FDA) to begin to test the drug
in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufac-tured. All clinical trials must be reviewed and ap-proved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.
Clinical Trials, Phase I—Researchers test the drug in a small group of people, usually between 20 and 80 healthy adult volunteers, to evaluate its initial safety and tolerability profile, deter-mine a safe dosage range, and identify potential side effects.
Clinical Trials, Phase II—The drug is given to volunteer patients, usually between 100 and 300, to see if it is effective, identify an optimal dose, and to further evaluate its short-term safety.
Clinical Trials, Phase III—The drug is given to a larger, more diverse patient population, often involving between 1,000 and 3,000 patients (but sometime many more thousands), to gener-
ate statistically significant evidence to confirm its safety and effectiveness. They are the lon-gest studies, and usually take place in multiple sites around the world.
New Drug Application (NDA)/Biologic License Application (BLA). Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more.
Approval. Once FDA approves an NDA or BLA, the new medicine becomes available for physi-cians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.
Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated $48.5 billion in research and develop-ment in 2012.
Developing a new medicine takes an average of 10-15 years; For every 5,000-10,000 compounds in the pipeline, only 1 is approved.
The Drug Development and Approval Process
PRE-
DIS
COV
ERY
DRUG DISCOVERY PRECLINICAL CLINICAL TRIALS FDA REVIEW LG-SCALE MFG
3 – 6 Y E A RS 6 – 7 Y E A RS 0. 5 – 2 Y E A RS
100 – 300 1,000 – 3,00020 –80
PHASE 2
PHASE 3
PHASE 1
IND
SU
BM
ITTE
D
ND
A S
UB
MIT
TED
PHA
SE 4
: PO
ST-M
AR
KET
ING
SU
RVEI
LLA
NCE
NUMBER OF VOLUNTEERS
ONE FDA-APPROVED
DRUG
5,000 – 10,000
COMPOUNDS
250 5
Drug Discovery and Development: A LONG, RISKY ROAD